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Abstract 
This thesis aims to investigate the role of the most known MAPKs, i.e. ERK, JNK and p38 
during the transformation of monocytes into dendritic cells (moDCs) and their subsequent 
maturation process, including antigen presentation in human-derived primary cultures. DCs 
play a crucial role in the antigen presentation during the immune response against different 
pathogens as well as in the activation of both CD8+ and CD4+ T-cells against cancer. In this 
particular case, it has been reported that patients suffering from different tumours show a 
common feature: a decreased number of moDCs, which bear a more immature phenotype. On 
these bases, we analysed moDCs derived both from healthy controls and cancer patients, in 
order to evaluate the eventual differences. According to our results and possibly due to the in 
vitro culture conditions, set to induce a normal maturation pathway in tumour patients’ 
derived moDCs, the response to the incubation in presence of selective MAPK inhibitors did 
not show paramount differences between cells derived from the healthy controls or from 
cancer patients. On the other site, we could show an interesting individual-dependent pattern 
of effects for each inhibitor, according to at least one of the analysed parameters. 
The most striking finding is that all the three MAPKs are required for the differentiation of 
human DCs from monocytes. Indeed, also the normal pro-proliferative kinase, ERK, in this 
specific case, is rather required to induce DC maturation, along with JNK and p38. 
We observed as well that the inhibition of all the analysed kinases caused strong effects on the 
morphology of the “mature cells”, which were not able to become adherent and kept their 
“immature” phenotype, i.e. round shape and loss of adherence. Such morphology appeared to 
be the most relevant cause of the impaired functionality of these cells, although not the only 
one. Indeed, ERK, JNK and p38 seem to work through positive feedback loops in order to 
induce and maintain human DC differentiation, in both phenotype and functionality. 
Further studies are required in order to investigate in details the mechanisms involved. 
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Zusammenfassung 
Das Ziel der vorliegenden Diplomarbeit war die Untersuchung der Aufgabe der bekannten 
MAPK (ERK, JNK und p38) in der Transdifferenzierung von Monozyten zu dendritischen 
Zellen (MoDCs) und dem folgenden Reifungsprozess mit der Antigenpräsentation in 
Primärkulturen von humanen Zellen. Dendritische Zellen (DCs) spielen eine entscheidende 
Rolle in der Antigenpräsentation bei der Immunantwort gegen verschiedene Pathogene, sowie 
in der Aktivierung von CD8+ und CD4+ T-Zellen gegen Krebs. Es wurde gezeigt, dass 
Patienten mit verschiedenen Tumoren ein gemeinsames Merkmal zeigen: eine verringerte 
Anzahl von MoDCs, die einen unreiferen Phänotyp aufweisen. Anhand dieser Tatsache 
untersuchten wir MoDCs von verschiedenen Kontrollpersonen und Krebspatienten, um 
mögliche Unterschiede zu finden. Aufgrund unserer Ergebnisse und wahrscheinlich wegen 
der Kulturbedingungen in vitro - die festgelegt wurden, um auch bei Tumorpatienten einen 
normalen Reifungsprozess der MoDCs zu induzieren - konnten wir nach Inkubation mit den 
verschiedenen MAPK-Inhibitoren keine überzeugenden Unterschiede in Zellen von gesunden 
Kontrollpersonen und von Krebspatienten entdecken. 
Andererseits konnten wir ein interessantes, personenabhängiges Muster von Effekten für 
jeden Inhibitor bei wenigstens einem der analysierten Parameter zeigen. 
Das Beeindruckenste ist, dass alle drei MAPK für die Differenzierung von humanen DCs aus 
Monozyten erforderlich sind. Die Proliferations-Kinase ERK wird in diesem speziellen Fall 
gemeinsam mit den Kinasen JNK und p38 zur Induktion der Reifung von DCs benötigt. Wir 
beobachteten auch, dass die Inhibierung der untersuchten Kinasen starke Effekte auf die 
Morphologie der „reifen Zellen“ hatte. Diese konnten nicht mehr adhärent wachsen und 
behielten somit ihren „unreifen“ Phänotyp, welcher sich durch eine runde Form der Zellen 
und einem Verlust der Anhaftung auszeichnet. Solch eine Morphologie scheint der 
maßgeblichste, aber nicht der einzige, Grund für die beeinträchtigte Funktionalität dieser 
Zellen zu sein. Tatsächlich bewerkstelligen ERK, JNK und p38 die Induktion und 
Aufrechterhaltung der phänotypischen und funktionellen Reifung von humanen DCs über 
positive Feedback-Loops. 
Weitere Studien sind erforderlich, um die involvierten Mechanismen im Detail zu 
untersuchen. 
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Introduction 
1. Dendritic cells – the sentinels of the immune system 
Dendritic cells (DCs) are the sentinels of the immune system, due to their function as potent 
antigen-presenting cells.  
1.1 Types and subsets of dendritic cells in humans 
DCs derive from hematopoietic stem cells and they can originate from both lymphoid and 
myeloid lineages. In humans, myeloid lineage DCs are considered as the “classical” DC. 
These cells originate from myeloid committed CD34+ progenitor cells. When this type of DC 
matures, it is known as an interstitial DC. In addition to be able to activate naïve CD4+ and 
CD8+ T-cells, interstitial DCs can induce differentiation of naïve B cells to antibody secreting 
plasma cells. Interstitial DCs are assumed to migrate to the lymphoid follicles and become 
follicular DCs. These DCs are activated by lipopolysaccharides (LPS) over toll-like-
receptor 4 (TLR4) during inflammation and infection. IL-4, produced in this inflammatory 
process, leads in combination with GM-CSF, to trans-differentiation of monocytes (mos) into 
MoDCs. Beside their function in activating cytotoxic T-lymphocyte (CTL) responses, they are 
also capable of stimulating CD4+ helper T-cells to prime memory CD8+ T-cell responses in 
their mature state1. Additionally, immature MoDCs can induce tolerance and are therefore 
important in avoidance of autoimmune-diseases. A less considered subtype of myeloid DCs 
are cord blood derived DCs, which can be compared to MoDCs, but are stronger inducers of 
tolerance and do not have the ability to mature. 
 
Myeloid committed CD34+ cells, which are CD14-negative can mature to what is called a 
Langerhans DC, in the presence of TGF-β. Langerhans DC are also capable of activating 
naïve T-cells, but not B-cells. Langerhans DC capture antigens, migrate to lymphoid tissues 
and present antigen to T-cells. A further subtype of myeloid DCs is constituted by the 
interferon-producing killer DCs (IKDC). They are efficient in cross-presentation of antigens 
on MHC I2 and are able to induce TH1 helper T-cells to produce interferon gamma (IFN-γ)3. 
 
The lymphoid DCs constitute to the DC subset that originates from CD34+ cells committed to 
the lymphoid lineage, are CD11c- and are driven to become DCs by IL-3. These DCs are 
referred to as plasmacytoid DCs. They have the capacity to produce IFN-α and reside in the 
T-cell compartment of lymphoid tissues. Plasmacytoid DCs received their name from 
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morphological similarities to antibody-producing plasma cells. Maturation of plasmacytoid 
DCs is induced by CpG and as a result, express Fc-Receptor, toll-like-receptor 7 (TLR7) and 
toll-like-receptor 9 (TLR9) through the activation of which, they produce type I interferons 
(interferon α; IFN-α)4.  
1.2 Functions and properties of dendritic cells 
Immature DCs (iDCs) are localized in peripheral tissues and are activated by stress events, 
e.g. ultraviolet irradiation, tissue damage or different kinds of pathogens. Furthermore, DCs 
can also be activated by tumour cells, which in turn are often invisible for the immune system 
either because of mimicking a physiological expression of surface markers or their production 
of molecules, such as interleukins (e.g. IL-10) which inhibit the maturation or the function of 
DCs.  
 
In their immature state, DCs can take up particles and microbes via phagocytosis, but they can 
also form pinocytic vesicles and take up solutes and extracellular fluid via macropinocytosis 
or express receptors that mediate adsorptive endocytosis. After antigen-uptake and followed 
maturation, DCs cannot take up other antigens anymore, due to the downregulation of 
phagocytic receptors. Because of the capture of the antigen in the peripheral tissues, the iDCs 
are activated, undergo maturation and become highly motile. In consequence, semi-mature 
DCs migrate toward the draining lymph nodes for presenting the antigen to T-cells5. This 
process is shown graphically in Fig. 1: T-cells (in blue) and B-cells (in pink) from the blood 
stream move to their distinct areas in the lymph node. Activated DCs (orange stellate profiles) 
migrate to the T-cell area of the lymph node6,7 where they cause activation of T-helper cells 
and cytotoxic T-cells. 
 
 
Fig. 1: Migration of dendritic cells into the draining lymph nodes  
(from: Nature reviews 449: 419-426; 2007) 
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Maturation of DCs is characterized by complex changes in phenotype and function, which are 
important for their activity in the innate immunity. The most obvious change in the phenotype 
is the morphological alteration: mature DCs (mDCs) possess branch-shape protrusion, as the 
name “dendritic (ancient greek for “tree”) cell” indicates. These dendrites are favourable for 
the cell-cell interactions, because due to the enlargement of the cell-surface a huge amount of 
cells can efficiently be activated from one DC at the same time. Beside the shape of the cell, 
also the expression pattern of the surface markers is changed. In iDCs only low expression of 
MHC molecules (HLA-DR), adhesion and co-stimulatory molecules (CD40, CD80, CD83, 
CXCR4, CCR4, CCR5) are found, whereas in mDCs these markers are expressed at a higher 
rate. Also the secretion of cytokines such as IL-10 or IL-12p70 is different according to the 
maturation stage; when DCs are fully mature the release of IL-10, which keeps DCs in their 
immature state is down-regulated, whereas IL-12p70, an important molecule for the 
development of TH1 type T-cell responses8,9 is up-regulated. Beside the inhibition of DC-
maturation, IL-10 is also responsible for the activation of regulatory T-cells, which in turn 
mediate immunosuppression10. 
1.3 A three step mechanism for T-cell activation 
To activate CD4+ as well as CD8+ T-cells, DCs have to present the antigen via MHC class I or 
class II receptor. This interaction is the first, preliminary contact between T-cells and DCs. As 
this signal is not enough to induce potent T-cell activation, another interaction has to be built. 
Therefore the receptors CD80 and CD86 on DCs can bind to CD28 on T-cells. If this second 
interaction is missing (e.g. if they are immature), DCs induce tolerance. The third bridge 
between DCs and T-cells is formed by CD40 on DCs and CD40L on CD4+ T-cells, which in 
turn can activate CD8+ T-cells. The interaction between CD40 and CD40L leads to IL-12 
production of the DC, which triggers the TH1 type T-cell responses. It is important that this 
CD40 signalling is only of transient nature, because a persistent interaction would lead to a 
blocked migration of the DC. 
1.4 Dendritic cells and cancer immunotherapy 
1.4.1 Work flow of in vitro culture of DCs for immunotherapy 
DCs are crucial for orchestrating the immune activation against the tumour upon endocytosis 
of immunogenic portion of tumour protein (peptides). Such peptides are internalized, 
processed and subsequently expressed over MHC receptors, leading to activation of tumour-
specific CTLs, which in turn attack the tumour. In cancer patients, this tumour recognition 
process through DCs is compromised. Indeed, cancer patients present less DCs, which are 
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kept to an immature state by the tumour-induced immunosuppressive environment11,12. An 
approach to stimulate DC activation through maturation in cancer patient is based on the in 
vitro culture, stimulation, maturation and reinjection of autologous DCs, derived from 
patients’ monocytes. This process is graphically shown in Fig. 2. In vitro cultured DCs have 
been shown to be resistant to immunosuppressive factors derived from the tumour and to be 
phenotypically and functionally stable in the absence of cytokines13,14. 
 
 
Fig. 2: Scheme of the workflow of DC-preparation for autologous DC-based active  
immunotherapy (modified from: Cancer immunol. Immunother. Rev.: Current  
approaches in DC generation; 2007) 
 
MoDCs can be generated by culture of peripheral blood mononuclear cells (PBMNCs), in 
presence of GM-CSF and IL-415,16. PBMNCs also contain CD34+ stem cells and CD14+ 
monocyte precursor cells, which give rise to DCs when cultured with these chemokines. With 
this method large quantities of DCs can be generated in vitro. There are some important 
points, which have to be considered in in vitro preparation of DCs. The application of mature 
DCs is crucial. There is clinical evidence, that administration of iDCs activate regulatory 
T-cells, leading to an undesired immunosuppression, instead of immune activation17. 
Maturation is induced by exposure of iDCs to pro-inflammatory mediators, such as IL-1β, 
agonists of co-stimulatory molecules like CD40L, the chemokine CCL16 or TLR agonists, 
like LPS. In in vitro culture of DCs, it is essential to use endotoxin-free materials, because 
even transient exposure of DC precursor monocytes to endotoxin impairs subsequent IL-12 
production18. Fully mature DCs, which lack IL-12 are unable to induce the favourable CD8+ 
T-cell response. 
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1.4.2 Loading strategies for DCs 
For the in vitro preparation of DCs, the choice of the antigen to be used for the loading step as 
well as the choice of the loading method is of paramount importance. Indeed, the antigen 
choice is upstream of the specificity and the sensitivity of the immune-response activation 
through DCs, while the loading method, mRNA or proteic antigen, directs the immune 
response towards the short-term (CTL) or the long-lasting (T-memory and TH) response, 
respectively. The ideal antigen would be expressed exclusively by the tumour and entirely not 
by normal cells, in order to avoid side-effects due to the unspecificity of the immune 
response. Up to date, several approaches are used for the DC-loading, including pulsing DCs 
with peptides or protein, applying lysates of the whole tumour or using a genetic approach, 
where DCs are transfected with DNA or mRNA. 
 
Using synthetic peptides for the DC-loading has the great advantage, that they can be 
produced synthetically, are therefore GMP-grade and there is no patient-derived tumour tissue 
needed, which quantity is often limited. Unfortunately, the use of synthetic peptides has some 
limitations: first, the peptides underlie MHC-restriction, which should be identified by MHC 
typing, next, the antigens of the tumour have to be known, to design an antigen peptide and at 
last, there is a lack of CD4+ helper T-cell activation19. 
 
Another method is the pulsing of DCs using tumour lysates, which contain all proteins of the 
tumour. Here the drawbacks are that there is a very high amount of tumour tissue needed and 
further, the lysates contain also peptides expressed from normal tissue, leading to 
immunoreactions against all cells20. 
 
Genetic approaches seems to be very promising, where either DNA or mRNA are presented to 
DCs using an active or passive transfection. One advantage is that the genetic constructs can 
easily be cloned and the genetic information of different antigens can be transferred to the 
DCs in one step, leading to a broader immune-response. Another advantage is that a passive 
transfection, where DNA or mRNA is just added as naked strands to the DCs, is very 
effortless. Until now, the loading with DNA was not very successful and due to the property 
to integrate into the host genome, loading of DNA is not very safe21. The use of mRNA can 
circumvent the safety problem, because it cannot integrate into the host genome, due to its 
transient expression, and it has also a higher efficiency in triggering the immune-response. 
Another important question about loading mRNA is the source of the nucleic acids: they can 
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be derived either from the patient himself, using PCR-amplified whole tumour mRNA or can 
be in vitro amplificated from mRNA of special genes, which are present in the tumour, but 
not in the normal tissue. There are only very few genes known, which fulfil these criteria, 
among these are carcinoembryonic antigen (CEA), telomerase reverse transcriptase (TERT) 
or survivin22,23,24. Due to the endogenous expression of the antigen, the peptides are expressed 
over the MHC class I. Immunization with mRNA-loaded DCs will activate CD8+ T-cells, but 
lacks CD4+ T-cell stimulation. 
 
1.4.3 Loading of DCs with Survivin-mRNA 
In the present diploma thesis, survivin mRNA was used for the loading of DCs because it is 
known to be overexpressed in common human cancers but absent in normal tissue. Survivin is 
also known as apoptosis inhibitor 4 (API4), due to its property to inhibit the programmed cell 
death and was discovered by Ambrosini et al in 1997 in a hybridization screening25. The 
inhibitor of apoptosis (IAP) encodes a protein with a size of 142 amino acids, which lacks a 
signal peptide and has no hydrophobic domain for membrane insertion. Therefore, it is not 
expressed on the cell surface. In healthy, adult tissue there is only a rare expression in thymus 
and placenta but it is absent in all other tissues. In the foetus, survivin is expressed in liver, 
kidney and to a lesser extent in fetal lung and brain at least until week 2126. 
 
Survivin is expressed in the G2/M phase of the cell cycle, where it is connected to the 
microtubules of the mitotic spindle and regulated by microtubule dynamics. In case of 
distorting this microtubule-survivin interaction, the antiapoptotic function of survivin is lost 
and leads to activation of caspase-3, which in turn induces cell death during mitosis. It can be 
suggested, that survivin is important for blocking of default apoptosis in G2/M phase and that 
the overexpression in cancer may also inhibit indispensable apoptosis, leading to 
transformation of cells27. Tumour suppressor p53 is important for the repression of survivin 
mRNA and protein and therefore has an important function in blocking of tumourigenesis28. 
 
The role of survivin in progression of tumour disease and in resistance to therapy was already 
shown. In diffuse large B-cell lymphomas and in soft tissue sarcoma, expression of survivin 
correlates with an unfavourable prognosis29,30. 
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2 Mitogen-activated protein kinases (MAPKs) 
2.1 Involvement of MAPK-pathways in the maturation of human dendritic 
cells (DCs) 
It has already been shown that the maturation of human monocyte-derived DCs (MoDCs) is 
induced by lipopolysaccharides (LPS), tumour necrosis factor α (TNFα) or interleukin-1β 
(IL-1β), which are signals that can also lead to activation of members of the MAPK-
pathways31,32. The role of MAPK-pathways in DC maturation is also demonstrated in a study 
where dose-dependent ultraviolet-B radiation mediates either maturation or apoptosis through 
p38-signalling in human MoDCs in vitro33.  
2.2 A three-modular system involved in various biological responses 
Mitogen-activated protein kinases (MAPKs) are main regulators of the cellular metabolism. 
Their function in multicellular organisms is important for stress response, apoptosis, 
proliferation, development and differentiation of cells. MAPKs are highly conserved 
serine/threonine kinases that can be found in eukaryotic organisms from yeast to human, such 
as Caenorhabditis elegans, Drosophila melanogaster and Xenopus laevis or tobacco or 
arabidopsis thaliana34. 
 
In mammals three subfamilies of MAPKs were discovered. All of them are acting as three-
modular systems. A MAPK kinase kinase (MAPKKK), which is activated by membrane 
associated events will lead to the activation of a MAPK kinase (MAPKK). Extracellular 
signals will lead to activation of one or more of the three different MAPK-pathways, 
depending on the nature of the signal from the outside of the cell. The MAPKKK has the 
ability to phosphorylate serine and threonine on the MAPKK. The MAPKK in turn can 
recognize a Thr-X-Tyr motif in the activation loop of a MAPK35. Due to their property to 
phosphorylate threonine as well as tyrosine, they are called dual-specificity kinases. Finally, 
the MAPK phosphorylates a number of substrates, which are either transcription factors 
(TFs), phospholipases, cytoskeleton-associated proteins or other protein kinases leading to 
additional influences of other biological pathways. 
 
Currently, the MAPK-pathways are supposed to act independently and it has been suggested 
that this independence is important to differentiate and control the three pathways. 
Furthermore, it is well known that there are connections between the pathways and that a 
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particular orchestration of activatory or inhibitory signals is important for the determination of 
cellular events. One example is the MAPKKK MEKK, which is activated by Rac and Cdc42, 
leading to a turn-on of the JNK-pathway, but which can be activated by Ras association too, 
and therefore stimulates both, the JNK- as well as the ERK-pathway36. 
 
 
Fig. 3: Schematic diagram of the three mammalian mitogen-activated protein kinase (MAPK)  
 signalling pathways (From: Nature immunology reviews 7: 202-212; 2007) 
 
2.2.1 Extracellular signal-regulated kinase pathway (ERK-pathway) 
The first step in the stimulation of the ERK-pathway is the activation of the MAPKKK Raf-1 
by Ras. Ras has in its active form a GTP in its binding pocket and is therefore able to bind to 
the NH2-terminal regulatory domain of Raf-1, which in turn will be bound to the plasma 
membrane and becomes activated37,38,39. Therefore, the tyrosines 340 and 341 are 
phosphorylated by membrane-bound tyrosine kinases40. B-Raf and A-Raf are homologs of 
Raf-1, which can be activated alternatively by Ras and result in the activation of the ERK-
pathway. B-Raf is activated by oncogenic Ras and does not need any other stimuli, whereas 
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A-Raf and Raf-1 need other signals to be strongly activated. These inputs can come from 
other kinases upstream of Raf-1, like Src or PKC or other tyrosine kinases41. Phosphorylation 
of Raf does not always lead to activation of the ERK-pathway. Indeed, phosphorylation of 
Raf-1 by its own downstream target ERK or cAMP-dependent protein kinase (PKC) leads to 
inhibition of Raf-1 activity42,43.  
 
The intermediate signal transducers of the ERK-pathway are two MAPKK, called MEK1 and 
MEK2. Both have similar amino acid sequences and can be activated by Raf-1 
phosphorylation. MEK1/2 act as dual specificity kinases, phosphorylating threonine and 
tyrosine of the MAPK ERK1/2. 
 
The active MAPK ERK1/2 itself can phosphorylate the serine or threonine amino acids from 
cytoplasmic substrates such as S6 kinase p90rsk, phospholipase A2, epidermal growth factor 
receptor (EGF-R) or microtubule-associated proteins (MAPs). ERK1/2 can translocate into 
the nucleus in its phosphorylated form and can activate a variety of TFs, again by 
phosphorylation. The most important TFs activated by ERK1/2 are Elk1, Ets1, c-Myc, STAT, 
SRF and TCF. The majority of the activated proteins and TFs correlate with cell growth and 
maturation, therefore it has been suggested that the ERK-pathway is responsible for 
maintenance and differentiation of cells. 
 
2.2.2 c-Jun N-terminal kinase pathway (JNK-pathway) 
JNK-pathway is mainly activated by cellular stress. Therefore, the MAPK JNK received the 
synonym stress-activated protein kinase (SAPK). The MAPKKK MEKK is activated by 
several stress events, such as heat shock, DNA-damage, oxidation events or hyperosmolarity. 
There is evidence, that the full length MEKK, which has a size of 196 kDa induces survival 
responses, whereas a 91kDa cleavage kinase fragment of MEKK serves as substrate for 
caspase-3 and therefore induces apoptosis44. 
 
Beside the stress events, the MAPKKK MEKK is also turned on by Rac and Cdc42, which 
are two members of the Rho family, both linked to cell differentiation and proliferation. 
MEKK itself phosphorylates MKK4 and MKK7. The active MKK4 and MKK7 are again 
dual-specificity kinases like MEK1/2 in the ERK-pathway and phosphorylate the threonine 
and tyrosine of the MAPK JNK. There are ten genes known encoding for JNK, leading to 
three splice variants named as JNK1 and JNK2 which are ubiquitously expressed and JNK3, 
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which expression is restricted to brain45, heart and testis46. The activated JNK leads to 
activation of SRF, TCF, ATF2, c-Jun, p53, Elk1 as well as to the homodimerization and 
activation of AP147,48. 
 
The effects of the JNK-pathway are versatile: they can lead to growth, differentiation and 
survival of cells, but can as well drive cells into programmed cell death as a response to 
cellular stress49. The important function of JNK-pathway in apoptosis was shown by a study 
inducing apoptosis in response to chemotherapeutic drugs50. For the survival of the cells the 
DNA-repair function is of great importance. Studies with JNK-inhibitors in cells treated with 
DNA-damaging drugs showed that the repair function is altered when the JNK-pathway is 
switched off 51. 
 
2.2.3 p38-pathway 
In mammals four different p38 enzymes are known, p38α, p38β, p38γ and p38δ. These 
isoforms show an identity of about 60% within their sequence and an identity to other MAPK 
family members of about 40-45%52. Like in JNK/SAPK signalling, p38-pathway can be 
activated by cellular stress events, such as UV-irradiation, osmotic shock, heat shock, 
lipopolysaccharides (LPS) or protein synthesis inhibitors and it is as well turned on by 
cytokines like IL-1 and TNF-α as well as G-protein coupled receptors (GPCR)53. Not only 
stress events and stress-related signals lead to activation of p38-pathway, but as well the 
constitutively active forms of Cdc42 and Rac may increase the activity of this MAPK-
pathway. 
 
Due to these activation events, the MAPKKKs TAK1, ASK1 or MLK3 are turned on and the 
MAPKKKs phosphorylate the MAPKKs MKK3 and MKK6 as well as MKK4 in few specific 
cell types. All of them are leading to induction of p38α and p38δ activation and in case of 
MKK4, the activation of the JNK-pathway takes place too54. 
 
MKK3 and MKK6 are dual specificity kinases like all of the MAPKK and therefore 
phosphorylate p38 on their threonine and tyrosine residues. The activated MAPK p38 itself 
phosphorylates a broad range of substrates, including cytoplasmic phospholipase A2, EGFR 
and Bcl-255,56,57. Beside these proteins, also a variety of TFs is activated by phospho-p38, the 
most important ones are ATF2, Elk1, TCF and Max. The TF Max can bind to the truncated 
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isoform of p38α, which phosphorylates Max, leading to heterodimerization with c-Myc, a 
substrate of the ERK-pathway58. 
 
The activation of the p38-pathway leads to proliferation, development, differentiation, 
immune responses as well as apoptosis. 
2.3 Inactivation of the MAPK-pathways in vivo and in vitro 
Considering the huge influences of the MAPK-pathways in the cellular metabolism, it appears 
clear, that in contrast to the activation, a negative regulation on the molecular level of the 
pathways is essential. Among the desensitization of the receptors, dissociation of signalling 
complexes from receptors and deactivation of pathway mediators, the most efficient 
inactivation is the dephosphorylation of the kinases by MAPK phosphatases59. 
 
Dephosphorylation does not only lead to an inactivation of the MAPK-pathways in vivo; 
indeed, blocking of phosphorylation is also a very useful tool in vitro to investigate the role of 
MAPK-pathways in ex-vivo cultured cell-lines or primary cells, such as monocyte-derived 
DCs. For each of the three MAPK-pathways selective inhibitors are available. For the present 
thesis, four different synthetic inhibitors are used, two against the ERK-pathway, one for 
inhibition of JNK-pathway and one for the p38-pathway. 
 
Inhibitors against ERK-signalling: 
For the inhibition of the ERK-signalling pathway, two synthetic agents are used: PD 98059 
and U 0126. 
 
• PD 98059 is a potent, selective and cell-permeable inhibitor of MEK1/2. It inhibits the 
phosphorylation of the MAPK ERK by MAPKKs MEK1/2 but does not inhibit the MAPK 
itself. The chemical structure of the inhibitor is shown in Fig. 4. 
  
Fig. 4: Chemical structure of the MEK1/2 inhibitor PD 98059 
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• The inhibitor U 0126 (Fig. 5) inhibits the MAPKKs MEK1/2 with a 100-fold higher 
potential than PD 98059. Beside the inhibition of MEK1/2 it is also a weak inhibitor of 
PKC, Raf, ERK, JNK, MEKK, MKK-3, MKK-4/SEK, MKK-6, Abl, Cdk2 and Cdk4. 
 
  
Fig. 5: Chemical structure of the MEK1/2 inhibitor U 0126 
 
Inhibitors against JNK-signalling: 
• To reveal the function of JNK-signalling in maturation of DCs, the inhibitor SP 600125 is 
used. It blocks selectively the phosphorylation of JNK by MAPKKs MKK4/7. The 
chemical structure is given in Fig. 6. 
  
Fig. 6: Chemical structure of the JNK inhibitor SP 600125 
 
Inhibitors against p38-signalling: 
• For the investigations of the third MAPK-pathway, a potent, cell-permeable, selective 
inhibitor against the phosphorylation of p38 is used. Fig. 7 shows the chemical structure of 
the synthetic inhibitor PD 169316. 
  
Fig. 7: Chemical structure of the p38 inhibitor PD 169316 
Structure of the project 
 
 - 17 - 
Structure of the project 
In the following scheme, an overview of the project structure is shown. After the isolation, the 
PBMNCs derived from the healthy controls or the patients suffering from cancer are taken 
into culture in a special growth medium and after a selective enrichment of monocytes, the 
trans-differentiation of these cells into iDCs is performed. The next step is the loading of the 
iDCs with Survivin mRNA. Finally, the loaded iDCs are fully matured into mDCs. 
Afterwards the mDCs are morphologically, phenotypically and functionally characterized by 
several assays, along with iDCs. 
 
In order to determine the exact time-points during DC maturation at which the analysed 
MAPK pathway play the most crucial roles and in order to investigate the effects of their 
relative inhibitors according to the time-point as well as to the duration of the administration, 
selective inhibitors of the ERK, JNK and p38 pathway were added to: 
A) monocyte cultures,  
B) iDCs cultured for 5 days, 
C) iDCs cultured for 5 days and loaded with survivin.  
The effects of the inhibitor addition were always compared with untreated cells cultured under 
the same conditions (D). 
 
 
Fig. 8: Structure of the project (black arrows A, B, C show points of inhibition;  
 blue arrow D demonstrates untreated portion of cells) 
 
Isolation of PBMNCs (healthy controls, cancer patients) 
Trans-differentiation of mos to iDCs
iDCs loading with survivin mRNA
Loaded iDCs maturation to mDCs
Characterization (morphologic, phenotypic and functional) 
A
B
C
D
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Material and Methods 
1 Culture of dendritic cells 
1.1 Monocyte enrichment 
Peripheral blood mononuclear cells (PBMNCs) from patients suffering from cancer are 
collected through leukapheresis in an associated and certified center. The apheresate is 
transported in appropriate temperature-controlled boxes between 8-20°C to CELL MED, 
where it is eventually processed in order to obtain an enriched phase of monocytes (mos) with 
minimal contaminations by lymphocytes, erythrocytes and platelets.  
Peripheral blood from healthy volunteers is collected directly at CELL MED by vein 
puncture, using Heparin-Vacutainer tubes and processed in the same way as the patients’ 
material, in order to enrich the mos phase. 
 
Shortly, the leukapheresate/whole blood is diluted 6X and 2.5X, respectively, in ACD 
solution (acid citrate dextrose; Baxter) and mixed with Ficoll (Biochrome) in a final ratio of 
1:1.5 before being centrifuged for 20 min at 2,000 rpm (break 0) at RT. Afterwards the 
interface is collected and centrifuged twice for 10 min at 1,200 rpm (break 9) at RT. Finally, 
the pellets are resuspended in plain medium for 2h at a final concentration of 2*106 mos/mL, 
after counting the number of mos with an automatical cell counter (CASY-1®, Schärfe 
System GmbH). Thereafter the non-adherent cells are washed out and the adherent ones are 
cultured as described in the following paragraph. The purity of the mos phase is measured by 
FACS analysis of CD14 and CD45. The eventual contaminations are evaluated by analysing 
the expression of CD3, CD16, CD19, CD41 and Glycophorine A (GPA). 
1.2 Primary cell culture 
To induce the switch from mos to immature dendritic cells (iDCs), the cells are cultured in 
CellGro DC medium (CellGenix), added up with 2,500U/mL GM-CSF (CellGenix) and 
1,000U/mL IL-4 (R&D), in a concentration of 2*106 mos/mL, at 37°C and 5% CO2 for 
5 days. Thereafter the iDCs are loaded with human Survivin mRNA in a concentration of 
150 ng/1*107 cells for 2h. Finally maturation of the DCs is induced by culturing them in 
presence of 100µg/mL Ribomunyl (Pierre Fabre) and 1,000U/mL INF-γ (R&D) for 24h at 
37°C and 5% CO2. 
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Since a hallmark of mature dendritic cells (mDCs) is their switch from non-adherent to 
adherent phenotype, Accutase is used to dislodge the mDCs from the plastic dish after 
washing out the non-adherent cells, eventually present in the supernatant. Shortly, the mDCs 
are incubated with Accutase (PAA Laboratories) for 5 min at 37°C. The cells are washed at 
1,200 rpm for 5 min at RT, resuspended in RPMI (Gibco) containing 2%FBS (Gibco) and 
used for further experiments. Alternatively the cells are frozen in Glycerol sterile solution 
(Mayrhofer). 
 
2 Chemical inhibition 
The following chemical inhibitors are used: 
 - MEK inhibitor (PD98059; LC), 20µM 
 - MEK inhibitor (U0126; LC), 40µM 
 - p38 inhibitor (PD169316; Sigma), 2.5µM  
 - JNK inhibitor (SP600125; Sigma), 5µM  
 
The inhibitors are applied either from the start of the culture, from the loading step or from 
the maturation step and when needed, are replaced every second day. 
 
3 Survivin mRNA preparation 
3.1 Cloning of Survivin c-DNA using TOPO TA cloning Kit (Invitrogen) 
TOPO TA cloning reaction 
0.5 to 4µL of TrueClone pCMV-DNA (100ng/µL), which contains the Survivin full-length 
cDNA (OriGene) is mixed with 1µL salt solution and the reaction is filled up to 5µL with 
water. Finally, 1µL TOPO vector (see Fig. 9) is added. The reaction is mixed gently and 
incubated for 5 min at RT. To achieve a higher number of colonies, the incubation time can be 
extended from 30 sec to 3 min. After the incubation, the reaction is placed on ice until 
transformation into one shot competent E.Coli (Invitrogen) is performed. 
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Fig. 9: pCR 2.1-TOPO cloning vector (Invitrogen) 
 
Transformation of one shot competent E.Coli 
For the transformation, E.Coli bacteria are thawed on ice for 3 min. Then 2µL of the 
TOPO TA cloning reaction are added and incubated for 5 to 30 min. Next a heat shock for 
30 sec at 42°C is performed and 250µL of SOC medium (Invitrogen) at RT are added. The 
transformed cells are incubated for 1h at 37°C and 250µL from the transformation is spread 
on pre-warmed LB agar plates containing Ampicillin in a concentration of 100µg/mL. Plates 
are incubated at maximum for 18h at 37°C and checked for positive clones. 
 
Liquid culture 
Each clone is transferred to a sterile tube containing 3mL of LB liquid media, supplemented 
with Ampicillin. The liquid culture is incubated overnight at 37°C on an orbital shaker at 
200 rpm. 
 
Reagents: 
LB agar + Ampicillin plates 
25g LB medium (MP Biomedicals) 
15g Agar agar (Carl Roth GmbH) 
The final volume is adjusted to 1L with water. The solution is autoclaved for 15-20 min and 
cooled down to 50°C. Finally it is added up with 100mg Ampicillin (Sigma). 
LB liquid media 
10g/L Tryptone (MP Biomedicals) 
5g/L Yeast Extract (MP Biomedicals) 
10g/L NaCl (Merck) 
Finally, the pH is adjusted to 7.0 with 1N NaOH and then the solution is autoclaved for  
15-20 min. 
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3.2 Plasmid isolation using Qiagen® plasmid isolation kit 
1.5 mL of the cell suspension are transferred to a 2 mL tube and centrifuged for 5 min at 
10,000 rpm. Then the supernatant is discarded and the rest of the E.coli suspension is pipetted 
into the tube containing the bacteria pellet. This is again centrifuged under the same 
conditions.  
 
The Kit contains Rnase A, which has to be solved in buffer P1. Each pellet is completely 
resuspended in 300 µL of buffer P1. This lysing step is the crucial step in the procedure. 
Afterwards 300 µL lysis buffer P2 are added and mixed by inverting the tube several times 
followed by an incubation step for 5 min at RT. This step is required to grant the degradation 
of genomic DNA of bacterial origin.  
After 5 min, 300 µL of the pre-cooled neutralization buffer P3 are added to the tube and 
mixed again by inverting the tube several times before performing an incubation step of 5 min 
on ice. The precipitation step is speeded up by the low temperature. Samples are centrifuged 
at 12,000 rpm for 10 min to get rid of cell debris.  
 
In the meantime, the Qiagen tips are equilibrated. Shortly, 1 mL of the equilibration buffer 
QBT is loaded on each column and let it completely flow through and dry at RT. After 
centrifugation, the clear supernatant containing the plasmid-DNA is collected and transferred 
to the Qiagen tips. The solution enters the column and after the whole supernatant is flown 
through it, the plasmid-DNA, which has instead been bound by the resin, is washed twice 
with 1 mL of QC buffer. 
 
After the washing step, the plasmid-DNA is eluted with QF buffer. Shortly, a fresh 1.5 mL 
tube is positioned under the column and 800 µL QF buffer are pipetted to each column. 
560 µL isopropanol (7 times volume) are added to the eluted plasmid-DNA and mixed by 
inverting the tube. Afterwards a centrifugation step at 12,000 rpm for 30 min is performed at 
RT. It is important to collect the DNA at RT, because at lower temperature also salts can be 
collected and therefore contaminate the DNA. The supernatant is discarded and 1 mL ethanol 
(70%) is added to each DNA-pellet, before performing a second centrifugation step of 7 min 
at 10,000 rpm. This procedure is repeated twice. Then the pellet is air-dried for 5 min at RT 
and dissolved in 100 µL 1xTE buffer. The plasmid DNA is stored on -20°C until further use. 
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3.3 Transcription of Survivin from a Miniprep-sample 
pCMV-Survivin linearization from Miniprep 
5µg plasmid are digested with XbaI (Fermentas). Shortly, the plasmid DNA is diluted in 
water to obtain a final concentration of 5µg plasmid in 50µL volume. Next 15µL of 10x 
buffer Tango (Fermentas) and 30 units XbaI restriction enzyme are added and the reaction is 
filled up to 153µL with water. The linearization is performed for 2h at 37°C. Thereafter the 
reaction is stopped and the cDNA is precipitated by adding 1/20 EDTA (0.5M; Pharmacia 
biotech), 1/10 Sodium acetate (3M; Sigma) and 2 volumes ethanol (100%; Merck). The 
reaction is incubated for 15 min at -20°C and afterwards centrifuged for 15 min at top speed. 
Next the supernatant is removed and the tube is re-spinned. The residual supernatant is 
removed with a fine-tipped pipette and the pellet is resuspended in 45µL water. 
 
Proteinase K treatment 
SDS (Sigma) is added to a final concentration of 0.5% and proteinase K (1mg/mL; Roche) is 
added to a final concentration of 200µg/mL to the linearized cDNA. The sample is thereafter 
incubated 30 min at 50°C. 
 
Phenol/Chloroform extraction 
DNA sample is added up to 100µL with water, 50µL phenol (Fluka) and 50µL chloroform 
(Fluka). The sample is mixed and centrifuged for 3 min at top speed. The aqueous phase is 
transferred into a fresh tube and centrifuged for 3 min at top speed to get rid of the remaining 
phenol. Next the aqueous phase is again transferred into a fresh tube and the equal volume of 
chloroform is added, centrifuged again for 3 min at high speed and again the aqueous phase is 
transferred into a fresh tube. 
 
To precipitate the DNA, 1/20 volume of EDTA (0.5M; Pharmacia biotech), 1/10 volume of 
sodium acetate (3M; Sigma) and 2 volumes of ethanol (100%; Merck) are added to the 
extracted DNA. The reagents are mixed to the sample and incubated for 15-20 min at -20°C. 
The supernatant is carefully removed and 700µL ethanol (70%; Merck) are added to wash the 
precipitate, followed by a centrifugation step for 10 min at top speed. The supernatant is 
removed with a fine-tipped pipette and 10µL water are added to the air-dried pellet. The 
concentration is determined by using a photometer (Peqlab). 
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Transcription reaction 
For the transcription reaction the reagents included in the mMessage mMachine kit (Ambion) 
are thawed. 10µL 2x NTP/CAP are mixed with 2µL of 10x reaction buffer, 2µl enzyme mix 
and 1µg linearized c- DNA template and the reaction is filled up to a final volume of 20µL 
with nuclease-free water. The reaction is mixed by short centrifugation and incubated for 2h 
at 37°C. Afterwards 1µL TURBO DNase is added, mixed well and incubated for 15 min at 
37°C. 
 
Cleaning and recovery of RNA 
Contents of the MEGAclear kit (Ambion) are brought to RT. The volume of the RNA sample 
is adjusted to 100µL with elution solution and mixed gently. 350µL binding solution 
concentrate are added and the reagents are mixed by pipetting. Next 250µL ethanol (100%; 
Merck) are added and again mixed by pipetting. The RNA mixture is then applied onto a filter 
cartridge and centrifuged for 1 min at 10,000xg. Afterwards the flow through is discarded and 
the filter cartridge is washed twice with 500µL washing solution, containing ethanol. Next the 
RNA is diluted with 50µL water. Therefore the filter cartridge is placed into a new collection 
tube and 50µL water are applied to the center of the filter, the cap is closed and the tube is 
incubated for 5 to 10 min at 65°C. The RNA is recovered by centrifugation for 1 min at RT. 
To maximize the RNA recovery the elution procedure is repeated with 50µL water. The RNA 
yield is determined by using a photometer and the quality is checked by real-time RT-PCR. 
 
RT-PCR 
First the RNA is transcribed into cDNA with superscript. Shortly 100ng random hexamers 
(1,250ng; Roche), 0.8mM dNTP Mix (10mM each dNTP; Amersham) are mixed with 
1µg RNA and filled up to a volume of 12µL with water. The reaction is heated up to 65°C for 
5 min and afterwards quick chilled on ice and spinned down. Thereafter 7µL of the master 
mix consisting of 4µL first-strand buffer (5x; Invitrogen), 2µL DTT (0.1M; Invitrogen) and 
1µL Rnase inhibitor (40U/µL; Promega) are added. The reagents are incubated for 2 min at 
25°C and then 1µL of SuperScript™ II reverse transcriptase (200U/µL; Invitrogen) is added 
and mixed by pipetting up and down. The mixture is incubated for 50 min at 42°C, followed 
by a heating step for 15 min at 70°C. The cDNA is diluted 1:5 with water and stored at -80°C 
until further use. 
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For the RT-PCR the following intron-spanding primers are used. The Primer design has been 
done by “Primer3” free software. 
 
hSurvivin primers: forward: 5’ – CTG GAC AGA GAA AGA GCC AAG – 3’ 
 reverse: 5’ – AGG GAA TAA ACC CTG GAA GTG – 3’ 
 
The master mix used in this reaction contains 2.5µL PCR buffer (10x; Invitrogen), 1.5mM 
MgCl2 (50mM; Invitrogen), 0.8mM dNTP mixture (10mM each dNTP; Amersham), 0.3µM 
each primer (10µM each), 1U Taq DNA Polymerase (5U/µl; Invitrogen) filled up to 22.5µL 
with water. 2.5µL of the diluted cDNA or, in case of the negative control, 2.5µL water are 
added to each aliquot of the master mix and the PCR reaction is performed in a cycler (MJ 
Research). 
 
The following conditions are used: 
 Primary denaturation 94°C 5 min 
 Denaturation 94°C 45 sec 
 Annealing 60°C 45 sec 40 cycles 
 Extension 72°C 45 sec 
 Final extension 72°C 5 min 
 
The PCR products are separated on a 2% agarose gel (Biozym), containing 10µg/mL 
Ethidium bromide (10mg/mL; Sigma), run for 45 min at 90 volt. As running buffer 1xTAE 
buffer is used. Each sample is mixed with 4µL loading dye (6x; Fermentas) and 7µL are 
loaded on the gel. As length marker, 2µg of a 100bp DNA ladder are used (0.5µg/µL; 
Fermentas). A picture of the gel is taken with a gel documentary system (Biozym). 
4 Analysis of the cells  
4.1 Morphology 
Before the cells are harvested after maturation, pictures are taken from the cultures with the 
help of an inverted light microscope (Axiovert, Zeiss), combined with a photo-camera 
(AxioCam, Zeiss) and relative software (Axiovision, Zeiss). Pictures are taken using a 40x 
objective and an exposure time of 20 sec. 
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4.2 Phenotype (FACS) 
For each staining 1*106cell/mL are resuspended in 50µL staining buffer (1x PBS 
supplemented with 1% BSA and 0.1% NaN3). Each aliquot of cells is incubated for 15 min at 
RT with the appropriate amount of FACS antibody according to Table 1, Table 2 and Table 3. 
After incubation, the cells are washed with 1.5mL of PBS at 800rpm at RT, resuspended in 
0.5mL staining buffer and further measured with a FACS device (Beckmann Coulter). 
 
To determine the concentration of mos after enriching this phase by Ficoll, the resultant cell 
suspension is analysed by FACS for the following CD markers: 
Antibody Fluorescence dye Company 
CD14 FITC Beckmann Coulter 
CD45 PC7 Beckmann Coulter 
Table 1: monitoring antibodies 
 
To determine the levels of eventual contaminations by leukocytes, erythrocytes, granulocytes 
and platelets, still present after Ficoll, the cell suspension is analysed by FACS for the 
following CD markers: 
Antibody Fluorescence dye Expressed on Company 
CD3 PC5 T-cells Beckmann Coulter 
CD16 PC5 Granulocytes Beckmann Coulter 
CD19 PE B-cells Beckmann Coulter 
CD41 FITC Platelets Beckmann Coulter 
Glycophorine A PE Erythrocytes Beckmann Coulter 
Table 2: antibodies for contamination control 
 
The stage of DC maturation is monitored after 5 days culture in presence of IL-4 and GM-
CSF and after inducing their maturation by Survivin-mRNA loading and addition of INF-γ 
and Ribomunyl, by analysing the expression of the following markers: 
Antibody Fluorescence dye Company 
CD40 PC5 Beckmann Coulter 
CXCR4 PE Becton Dickinson 
CD80 FITC Beckmann Coulter 
CD83 PC5 Beckmann Coulter 
CCR5 FITC Becton Dickinson 
HLA-DR PC5 Beckmann Coulter 
CCR4 PE Becton Dickinson 
Table 3: antibodies for phenotype determination 
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The calculation is done by using the quadrant statistics and is given in percentage of positive 
cells relative to the total cell number. 
4.3 ELISA (IL-10 and IL-12 secretion) 
The ELISA is performed starting from supernatant collected from each cell culture set after 
5 days culture in presence of IL-4 and GM-CSF and after inducing DC maturation by 
Survivin-mRNA loading and addition of INF-γ and Ribomunyl. Human IL-10 and IL-12p70 
secretion is analysed following OptEIA ELISA Sets (BD Pharmingen) protocol. 
 
Shortly, the required number of wells for the analysis are coated with 100µL of diluted IL-10 
or IL-12 antibody (dilution in coating buffer as recommended in the lot-specific analysis 
certificate) and incubated overnight at 4°C. Next day the plate is washed thrice and a blocking 
step is performed for 1 h at RT with 200µL of the supplied assay diluent. The plate is again 
washed for 3 times. Next 100µL of each sample (1:2 diluted) as well as 100µL of each 
standard are applied to the wells in duplicate and incubated for 2h at RT. Afterwards a 
washing step is performed for 5 times. Next 100µL of the working detector reagent are added 
to each well. The working detector reagent is a one-step Biotin/Streptavidin reagent and 
consists of the diluted, biotinylated IL-10 or IL-12 detection antibody and streptavidin 
horseradish peroxidase. After 30 min the plate is washed again for 7 times. Each washing step 
has a soaking time of 1 min. Next 100µL of substrate solution are added and incubated for 
30 min at RT in the dark. To stop the reaction 50µL of a stop solution is pipetted to each well 
and the plate is read on a photometer (BioRad) at 450nm within 30 min with a wavelength 
correction of 570nm. The absorbance is directly related to the amount of detected interleukin 
and corresponding to the standard dilutions. 
4.4 Proliferation Assay (Mixed lymphocyte reaction) 
DCs are co-cultured at a final concentration of 1*106 cells/well in a 96-well U-bottom plate 
with the non-adherent fraction of Ficoll-separated PBMNCs from a healthy donor at a final 
concentration of 1*104 cells/well in RPMI with 2% FBS (Gibco), supplemented with 
10% AlamarBlue® at a final volume of 150µL. Proliferation causes reduction of the dye 
changing from oxidized (non-fluorescent, blue) form to reduced (fluorescent, red) form. For 
2 to 7 days, every 4 to 12h, the absorbance is measured on a plate-reader (SLT-Tecan) at 
595nm with reference wavelength at 620nm. 
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4.5 Phagocytosis Assay (FITC-Dextran uptake) 
For each sample 3 measurements are done: one control, one for spontaneous phagocytosis and 
one to check the induced phagocytosis. Therefore DCs are plated in a density of 1*106 cells 
on a 6-well-plate. Each well is filled with 1.5mL of RPMI 1640 (Gibco), supplemented with 
2% FBS (Gibco) and 0.5µg/µL of FITC-dextran (Sigma) are added to well 2 (spontaneous 
phagocytosis) and well 3 (induced phagocytosis). 300ng/mL of CCL19 (Sigma) are added to 
the 3rd well only (induced phagocytosis). The cells are incubated for 2h with or without 
FITC-dextran at 37°C and washed twice in cold PBS, centrifuged for 5 min at 1,200rpm at 
RT, before resuspending them in 0.5mL of cold PBS and measuring with a FACS device 
(Becton Dickinson). The phagocytosis activity is given in percentage of phagocyting cells 
relative to total cell number. 
4.6 Migration Assay (Transwell assay) 
To measure the migration potentiality of the cultured DCs, 1*106 cells are transferred to a  
6-well plate. For each sample 3 wells are used: one well where the total cell number is 
determined, one for spontaneous migration and one for induced migration. The lower part of 
each well of the 6-well plate is filled with 1.5mL of RPMI supplemented with 2% FBS. 
300ng/mL of CCL19 are added to the 3rd well only (induced migration). Thereafter the filter 
is inserted and 500µL of the cell suspension are added to the well and incubated for 2h at 
37°C at 5% CO2. Afterwards 1.5 mL and 500µL of 8% paraformaldehyde (PFA; Sigma) are 
added to the medium and to the filter, respectively, in order to reach a final concentration of 
4% PFA and the plates are incubated for 10 min at RT. Afterwards the wells are washed twice 
with 1x PBS. 
 
Finally the upper surface of the filter is scraped only in the second and third well 
(spontaneous and induced migration) with a cotton-tipped swab and the remained cells are 
stained with a solution made of 0.2% crystal violet (Sigma) in 20% methanol (Merck) for 
5 min at RT. The cells in the first well are also stained, but not scraped before, because with 
this well the total cell number is determined. Thereafter the inserts are rinsed with water to get 
rid of the excess staining solution and air-dried. Afterwards the membranes are cut out of the 
plastic ring, placed on a glass slide and mounted with Entellan (Merck). Each membrane is 
photographed, the cells are counted and the cell number is given in percentage of total cells 
(well 1). 
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4.7 Viability assay 
Viability test is used to determine the inhibitors toxicity depending either on their final 
concentration (unspecific) or on their effects upon the different MAPK-pathways (specific). 
The viability test is performed by and according to the protocol included in the Annexin V-
FITC apoptosis detection kit (Biovision). Shortly 1*105 cells are resuspended in 500µL of 1x 
binding buffer. Next 5µL of Annexin V-FITC and 5µL of propidium iodide (PI) are added 
and incubated for 5 min at RT in the dark. The Annexin V-FITC binding is analysed by flow 
cytometry using FITC signal detector and PI staining by the phycoerythrin emission signal 
detector. 
4.8 Western Blot 
Protein Extraction 
To avoid protein degradation, all steps are performed on ice. First 2*106 cells are thawed in 
100µL Frackelton buffer (preparation see Table 4 and Table 5), vortexed and incubated for 
20 min at 4°C to gain cytoplasmic proteins. After another vortexing step, the cells are 
centrifuged for 20 min at 20,000g at 4°C and the nuclear pellet is separated from the 
supernatant, which corresponds to the cytoplasmic fraction. At last 100µL of the cytoplasmic 
protein fractions are mixed with 25µL of 5x SDS sample buffer added up with DTT 100mM 
just before use. The samples are heated up to 75°C for 5 min before loading. 
 
 Stock solution Amount added 
Tris-HCl 10mM 0.24g 
Na4P207 30mM 2.7g 
NaCI 30mM 0.6g 
Triton 100x  2mL 
Deionised water  Fill up to 200mL 
Table 4: Frackelton buffer concentrate, stored at 4°C until further use 
 
Added just before use: 
 Stock solution 
Final 
concentration 
Dilution
fV = 1.2mL 
Frackelton Buffer 
NaF 1M 50mM 1:20 60µL 
Na3VO4 100mM 0.1mM 1:1000 1.2µL 
Protease inhibitor 
cocktail   1:25 48µL 
OA 100mM 0.1mM 1:1000 1.2µL 
PMSF 0.1M 1mM 1:100 12µL 
Table 5: Frackelton buffer working solution, prepared prior before use 
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SDS-PAGE 
For the electrophoresis a SDS-Polyacrylamidgel is prepared, therefore the miniprotean III 
system is used (Biorad). The 10% polyacrylamid separating gel is prepared according to the 
following formula: 
 1 small gel 
Tris-HCl, pH 8.8 1.5 M 3mL 
Bis/Acrylamide 30% (Biorad) 4mL 
SDS 20% (Sigma) 60µL 
Water 5mL 
APS 10% (Sigma) 48µL 
TEMED (Sigma) 24µL 
Table 6: Running gel for a 10% SDS-Polyacrylamidgel 
 
The gel is covered with isopropanol and 15 min time is given for polymerisation at RT. The 
isopropanol is discarded and the stacking gel solution is layered on top of the separating gel, 
which is prepared according to the following table: 
 1 small gel 
Tris-HCl, pH 6.8 1.5 M 1mL 
Bis/Acrylamide 30% 0.5mL 
SDS 20% 20µL 
Water 1.25mL 
APS 10% 24µL 
TEMED 12µL 
Table 7: Stacking gel for a SDS-Polyacrylamidgel 
 
Finally a comb is inserted in the stacking gel, which is let to polymerize for 15 min. After 
removing the comb, the slots are filled with running buffer and the gel is inserted into an 
electrophoresis chamber that is in turn filled with running buffer. Next 5µL of the prestained 
protein marker (Fermentas) and 5µg of each sample are loaded on the gel. The electrophoresis 
is performed for about 90 min at 160V. 
 
Immunoblot and Ponceau Red staining 
After SDS-PAGE, the proteins are transferred from the polyacrylamid gel to a nitrocellulose 
membrane using 1x transfer buffer. Blotting is performed for 1h at 30V using a semi-dry 
blotting apparatus. The immunoblotting sandwich is made up of three pre-wetted filter papers, 
cut to the size of the gel. Next the gel is placed on the filter papers and covered with the pre-
equilibrated membrane. At last another three pre-wetted filter papers are placed on top. The 
sandwich is oriented in a way that the gel is at the cathode and the membrane at the anode. 
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After the transfer, the membrane is stained with Ponceau Red in order to determine the quality 
of the blotting. Afterwards, the membrane is rinsed once in water and twice in TBST until all 
the red staining is completely removed. 
 
Reagents: 
• 5x SDS sample buffer: 1g Tris (Sigma), 12.5g SDS (Sigma), 12.5mL glycerol (Fluka), 
6mg bromphenol blue (Biorad) dissolved in deionised water, brought to pH 6.8 and added 
up with 100mM DTT (Invitrogen) just before use 
• 10% APS: 1g ammonium persulphate (Sigma) dissolved in 10mL of deionised water, 
stored at -20°C 
• Ponceau Red 10x (stock solution): 2g Ponceau S (Serva), 30g Trichloracetic acid (Merck), 
30g Sulphoalocyclic acid (Merck), deionised water to 100mL 
• 10x Running buffer: 30 g. TRIS-base (Sigma); 144 g Glycine (Fluka); 50 mL SDS 
(Sigma) 20% and water to 1L Separation gel buffer (pH 8.8): 1.5M Tris-HCl, 0.4% SDS, 
deionised water to 1L 
• Stacking gel buffer (pH 6.8): 0.5M Tris-HCl, 0.4% SDS, deionised water to 1L 
• 10x Blotting buffer: 29g Glycine (Merck), 58g Tris-Base (Sigma), 3.7g SDS, deionised 
water to 1L 
• 1x Blotting buffer: 10% 10X blotting buffer, 20% methanol (Merck), deionised to 1L 
• 10x TBS: 250mM Tris, 1.5M NaCl (Merck); pH 8.0, deionised water to 1L 
• TBST: 100mL 10x TBS, 500 µL Tween-20 (Promega), deionised water to 1L 
 
Incubation with the antibodies 
Non-specific binding is blocked by incubating the membrane for 1h in a solution of TBST 
added up with 5% powder milk, followed by two washing steps with TBST for 10 min. 
Finally the membrane is incubated overnight with the appropriate primary antibody diluted in 
TBST. 
 
The day after the membrane is washed 3 times in TBST and subsequently incubated for 1h 
with the appropriate secondary antibody, diluted in TBST. Thereafter, the membrane is 
washed three times for 10 min with TBST. 
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The following antibodies are used: 
B-Raf C-terminal (Santa Cruz) 1:500 Rabbit polyclonal 
C-Raf (BD Transduction Laboratories) 1:1.000 Mouse monoclonal 
MEK 1/2 (Cell Signalling Technology) 1:500 Rabbit polyclonal 
pMEK 1/2 (Cell Signalling Technology) 1:500 Rabbit polyclonal 
JNK (Cell Signalling Technology) 1:1000 Rabbit polyclonal 
pJNK (Cell Signalling Technology) 1:1000 Rabbit polyclonal 
p38 (Santa Cruz) 1:1000 Rabbit polyclonal 
p-p38 (Santa Cruz) 1:200 Rabbit polyclonal 
Actin (Santa Cruz) 1:500 Goat polyclonal 
Table 8: Primary antibodies and secondary antibodies used for western blots 
 
ECL detection 
After the immunoblotting the detection is performed by incubating the membrane for 3 min 
with 1mL of previously mixed Luminol/Enhancer Solution and Stable Peroxide-Solution 
(Pierce). Excess detection buffer is poured off and the membrane is positioned between two 
transparent foils and thereafter placed in a film cassette. Finally, it is exposed to an ECL-
hyperfilm (Amersham) in the dark room for a time comprised between 10 sec and 1h, 
depending on the strength of the signal. 
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Results 
All the experiments described in this session are performed with human dendritic cells 
derived either from whole blood of healthy volunteers (controls 1-6) or from surplus from 
leukaphereses of patients suffering from different types of tumours. For details see Table 9. 
Name sex Age [in years] type of cancer 
Control 1 female 30 - 
Control 2 female 29 - 
Control 3 female 34 - 
Control 4 female 24 - 
Control 5 female 36 - 
Control 6 male 22 - 
Patient A male 52 colon 
Patient B female 50 breast 
Patient C female 59 ovarian 
Patient D female 51 breast 
Patient E female 47 ovarian 
Table 9: Description of controls and patients 
 
Due to a quantitative limitation of cells, not all the experiments could be carried out with the 
same patients. 
1 Morphology 
To determine whether the addition of different selective MAPK inhibitors affects the 
phenotype of human dendritic cells, we observed the morphology of the analysed DCs in 
presence and in absence of the following inhibitors: Control, PD = MEK-inhibitor PD 98095, 
U = MEK-inhibitor U 0126, JNK = JNK-inhibitor SP 600125, p38 = p38 inhibitor 
PD 169316. In Fig. 10 it is possible to compare the effects of different MAPK inhibitors, 
added from the start of the in vitro culture, on the morphology of loaded, fully mature DCs. 
 
  
Control PD 98059 
MEK-inhibitor 
U 0126 
MEK-inhibitor 
SP 600125 
JNK-inhibitor 
PD 98095 
p38-inhibitor 
Fig. 10: Morphology of DCs cultured from the start in absence (control) or in presence of selective  
 MAPK inhibitors (MEK-inhibitor PD 98059, MEK-inhibitor U 0126, JNK-inhibitor,  
 p38-inhibitor) at the start of the culture 
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Untreated mDCs grew adherent and showed the typical stellate shape, whereas upon MEK-
inhibition with either PD 98059 or U 0126, the cells did not attach to the plastic anymore and 
revealed DCs with only rare extensions, which is a hallmark of the immature phenotype. Such 
immature phenotype was even strengthened upon addition of either JNK- or p38-inhibitors. 
Indeed, in these specific cases, the DCs completely lost the adherent, mature phenotype in 
favour of the immature one, characterized by a fully non-adherent pattern accompanied by the 
complete loss of dendrites formation. Moreover, JNK- or p38-inhibition was characterized by 
a reduced viability, a fact that may be related to the well known pro-apoptotic features of 
these two pathways.  
2 Phenotype (FACS) 
Since the addition of different selective MAPK inhibitors significantly modified the normal 
phenotype of mature DCs, we further investigated whether such a difference correlates as well 
with a modification in the expression of the surface markers, which are known to be increased 
during human DC maturation. Shortly, we analysed by FACS DCs derived either from 
healthy controls or patients for the following markers: CD80, CD83, CD40, CXCR4, CCR5, 
CCR4 and HLA-DR after the first 5 days of culture in presence of IL-4 and GM-CSF (iDCs) 
and 24h after loading and maturation. 
2.1 Addition of selective MAPK inhibitors from the start 
We added the MAPK inhibitors from the very start of the culture of DCs derived from one 
healthy control (control 1) respectively one patient (patient A). 
 
2.1.1 iDCs 
After 5 days in culture, untreated iDCs derived from healthy control showed higher levels of 
CD40, CD80 and HLA-DR in comparison with untreated iDCs derived from the patient. 
Reversely, untreated iDCs derived from the patient showed higher levels of CCR5 and CCR4 
in comparison with untreated iDCs derived from the healthy control. 
 
MEK inhibition by PD 98059 strongly decreased the expression of CD40, CXCR4, CD80 and 
HLA-DR on the surface of iDCs derived from healthy control, without significantly affecting 
the expression of CD83, CCR4 and CCR5. On the other hand PD 98059 addition to iDCs 
derived from patients slightly increased the expression of CD40, slightly decreased the 
expression of HLA-DR but did not affect the expression of CD83 and CXCR4 and strongly 
decreased CD80, CCR5 and CCR4 expression. 
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MEK-inhibitor U 0126 led to a slightly decrease of CD40 and a stronger decrease of CXCR4 
and CD80, but did not affect the expression of CD83, CCR5 and HLA-DR in the healthy 
control while strongly increasing CCR4 expression. Whereas on the patients’ iDCs the 
expression of CD40, CD80, CCR5, HLA-DR and CCR4 was decreased, the levels of CXCR4 
and CD83 remained stable. 
 
Treating iDCs with JNK-inhibitor SP 600125 did not affect CD83 expression rate, caused a 
strong decrease of CD40 and CD80 expression combined with a strong increase of CXCR4, 
CCR5 and CCR4 expression on the surface of DCs derived both from patient and from 
healthy control. While such inhibitor caused as well as a strong decrease of HLA-DR in iDCs 
derived from the healthy control, iDCs derived from the patient showed no change in the 
expression of HLA-DR compared to the untreated cells.  
 
The results obtained upon SP 600125 addition to iDCs culture were completely mimicked by 
incubation with the p38-inhibitor PD 169316, with one exception: CD83 the expression of 
which greatly rose upon incubation in presence of PD 169316 on the surface of patient-
derived iDCs, while being slightly increased on the surface of healthy control-derived iDCs. 
 
These results showed that iDCs respond differently to MAPKs inhibition from DCs, 
according to their source: cancer patients or healthy control. Such discrepancy combined with 
the different phenotype regarding CD40, CD80, CCR5, HLA-DR and CCR4 showed by 
untreated iDCs derived from healthy people or from cancer patients is in agreement with the 
finding that DCs isolated from cancer patients retain a more immature phenotype, in 
comparison to that of iDCs derived from healthy people (ref 60). Indeed, patient-derived iDCs 
express less CD40, HLA-DR and CD80 in comparison to iDCs isolated from healthy controls. 
Interestingly, the inhibition of MEK either by PD 98059 or by U 0126 caused a more 
immature phenotype in comparison to untreated cells. This fact was particularly evident upon 
addition of PD 98059 and mostly in healthy control-derived DCs. The effects were indeed far 
reduced in patient-derived DCs. Since MEK-pathway usually correlates with cell proliferation 
and undifferentiated state (ref 61), it is very curious to see that such effects are not 
reproducible in human DCs, cultured in vitro. Possibly, this characteristic is due to the fact 
that iDCs are already “differentiated” cells, derived from monocytes, which do not show any 
in vitro proliferative capability. For such cells, the importance of the MEK-pathway may 
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reside elsewhere from mere proliferation enhancement and maintenance of the 
undifferentiated state. 
As expected, inhibition of JNK and of p38 pathway did correlate with a more immature 
phenotype, according to the finding that such MAPK pathways correlate with cell 
differentiation (ref 62,63). In this case, too, the effects of the inhibitors were particularly evident 
on iDCs derived from healthy controls in comparison to those patient-derived. Such effects 
were stronger regarding CXCR4 and CD80 expression. Curiously, CD83 expression increased 
upon PD 169316 but not upon SP 600125, suggesting that the two MAPKs may affect 
different aspects of DCs maturation. 
 
 
Immature cells – Inhibition from the start of the culture 
Control 1
0
20
40
60
80
100
C
D
40
C
XC
R
4
C
D
80
C
D
83
C
C
R
5
H
LA
-D
R
C
C
R
4
Marker
Po
si
tiv
e 
ce
lls
 in
 %
 o
f
to
ta
l c
el
l n
um
be
r
 
Patient A (colon)
0
20
40
60
80
100
C
D
40
C
XC
R
4
C
D
80
C
D
83
C
C
R
5
H
LA
-D
R
C
C
R
4
Marker
Control
PD
U
JNK-Inh.
p38 Inh.
Fig. 11: Phenotype of immature cells inhibited from the start of the culture  
 (two different humans: control 1 and patient A) 
 
2.1.2 mDCs 
After 5 days in culture, cells were loaded with Survivin by passive transfection (6h) and after 
maturation for 24h upon addition of the maturing cocktail. Fully mature cells were harvested 
and tested for surface markers expression. 
 
Upon maturation, both patient- and healthy donor-derived, untreated DCs showed a 
completely new pattern of expression regarding the analysed surface markers in comparison 
with that shown by the respectively iDCs. Indeed, CD80, CD83, CCR5 and CCR4 expression 
strongly increased in comparison to that detectable on the respective iDCs. HLA-DR and 
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CD40 expression remained high on mDC, derived from healthy donor and remarkably 
increased on the surface of mDCs, derived from cancer patient. These data suggest that, as 
reported in literature (ref 64), in vitro cultured patient-derived DC can be fully mature, to 
levels comparable to those shown by healthy donor-derived DCs. The only true difference in 
the marker expression patterns between mDCs derived either from healthy donor or patient 
regards CD83 expression, which remained lower on the latter. On the other side, slightly 
differences were detectable in CXCR4 expression, which was higher in patient-derived in 
comparison with healthy donor-derived DCs and in CD80 expression, which showed the 
opposite pattern. 
 
Prolonged incubation with MEK-inhibitor PD 98059 led to a strong decrease of all the 
analysed markers on the surface of healthy control-derived DCs as well as of patient-derived 
DCs, with the exception of CD83, which expression on patient-derived DCs, opposite to 
healthy control-derived DCs, appeared to be only slightly, if ever, affected by the addition of 
PD 98059.  
 
Treatment with the inhibitor U 0126 mimicked the effects of PD 98059 but as seen as well in 
the iDCs, to less extend. Indeed, U 0126 addition decreased the expression of CXCR4, CD83, 
CCR5 and CCR4 on the surface of healthy control-derived DCs as well as of all the analysed 
markers on the surface of against the MEK-pathway mainly impaired the levels of CXCR4, 
CD83, CCR5 expression of patient-derived DCs. According to these data, the effects of 
U 0126 were stronger on patient-derived DCs in comparison with healthy control-derived 
DCs, suggesting that this inhibitor block a part of the MEK-pathway, which has a more 
crucial role in patient-derived DCs. Again, the MEK-pathway seems to be involved in DC 
maturation rather than proliferation and maintenance of the immature state.  
 
As expected, JNK-inhibition diminished expression of all surface markers in the healthy 
control as well as in the patient, compared to the cells grown without inhibitor, suggesting 
that this MAPK is deputed to induce the terminal maturation of human DCs. 
 
As expected, the inhibition of the p38-pathway mimicked the effects showed upon addition of 
JNK-inhibitor. Interestingly, again, the inhibition of p38 was less effective on the expression 
of CD83 on patient-derived DCs, suggesting that cancer may uncouple the expression of this 
marker from the p38-pathway.  
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In summary, these data suggest that during DCs maturation all three MAPKs (MEK, JNK and 
p38) played together a pivotal role towards cell differentiation, in contrast to the most 
common pattern of action, which sees MEK playing pro proliferation and maintenance of the 
undifferentiated state and versus the pro-differentiation kinases JNK and p38.  
The results showed as well that cancer impairs DCs differentiation both by actively affecting 
cell phenotype and by making DCs more prone to respond to MEK inhibition, especially 
through the pathway selectively blocked by U 0126. 
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Fig. 12: Phenotype of mature cells inhibited from the start of the culture  
 (two different humans: control 1 and patient A) 
 
2.2 Addition of selective MAPK inhibitors from the loading step 
In order to determine whether the effects shown upon selective inhibition of different MAPKs 
were due to the prolonged exposure to such substances or whether their effects upon the DC 
maturation depend as well or principally on the time point at which they are added, we tested 
the effects of selective inhibition of MEK, JNK and p38, upon addition of the respective 
inhibitor just before performing the loading step. 
 
The addition of the selective MEK inhibitor PD 98059 just before the loading step mimicked 
the effects shown by the addition of the same inhibitor from the very start of the culture in 
both healthy donor- and patient-derived DCs, the only small detectable differences being the 
fact that in this case, the negative effects on HLA-DR were lower in both samples, whereas 
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they increased on CCR4 in patient-derived DCs, in comparison to the prolonged incubation 
with the same inhibitor. These data suggest that the decreasing rate of HLA-DR expression 
directly correlates with the exposure length to such inhibitor, whereas the effects on CCR4, at 
least in patient-derived DCs are increased by a timely addition of PD 98059, suggesting that a 
short but precise exposure to the inhibitor may be more effective than a durable, not-time-
aimed incubation. 
 
More interestingly, the effects of the selective MEK inhibitor U 0126 on the surface of 
healthy control-derived DCs were far stronger upon addition just before the loading step than 
upon prolonged incubation from the start of the culture. This fact was particularly evident 
from the strong impairment of CD40, CD80, CD83 and CCR5. On the contrary, the addition 
of the selective MEK inhibitor U 0126 just before the loading step mimicked the effects 
shown by the addition of the same inhibitor from the very start of the culture in patient-
derived DCs. Such effect may support the idea that U 0126 blocks a MEK-pathway, which is 
important for the switching towards maturation for healthy DCs and which becomes active 
during the antigen encountering. At the same time, it shows that timely inhibition through 
U 0126 may be more effective than a prolonged exposure, which in turn can make the cells 
refractory to its action. The fact that U 0126 timely and prolonged inhibitions gave the same 
effects on patient-derived DCs may suggest that MEK plays a role on the differentiation of 
these cells already at the stage of iDCs, before the antigen encountering due to cancer related 
effects. 
 
JNK-inhibition just before the loading step completely mimicked the effects shown upon 
addition of the same inhibitor from the very start of cell culture, suggesting that the effects of 
this inhibition upon DC maturation do depend more on the check-point of administration 
rather than on its duration.  
 
Treatment with p38-inhibitor reveals a similar result to JNK-inhibitor addition. In this case, 
too, both p38 and JNK seem to be involved as expected, in the differentiation of the analysed 
cells. Due to the minor differences showed upon addition of these two inhibitors in the effects 
on healthy donor-derived versus patient-derived DCs, it seems that such kinases are not really 
affected by the tumour establishment. 
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Fig. 13: Phenotype of mature cells inhibited from the loading with Survivin mRNA  
 (two different humans: control 1 and patient A) 
 
2.3 Addition of selective MAPK inhibitors from the maturation step 
In order to further evaluate the role of MEK, JNK and p38 in different steps of DCs 
maturation, we tested the effects of selective inhibition of MEK, JNK and p38, upon addition 
of the respective inhibitor just before adding the maturation cocktail and after the loading 
step.  
 
The addition of the selective MEK inhibitor PD 98059 just before maturing healthy donor-
derived DCs mimicked the effects shown by the addition of the same inhibitor from the very 
start of the culture or just before the loading step. Therefore the data suggest that, at least in in 
vitro culture, MEK plays a pivotal role for the final DC maturation upon maturation induction 
and that the inhibition of such a pathway rather depends on the check-point of the 
administration than on the duration of the treatment. The addition of the selective MEK 
inhibitor PD 98059 just before maturing patient-derived DCs almost completely mimicked the 
effects shown by the addition of the same inhibitor just before the loading step, with the 
following exceptions. In this case, the inhibition of CD40 expression results weaker and more 
similar to that shown upon prolonged exposure to the inhibitor, whereas the opposite is true 
about the expression of CD80 and CD83. Again the phenotypical expression of such markers 
mimicked that shown upon prolonged exposure to the inhibitor. Therefore the data suggest 
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that, at least in in vitro culture, MEK plays a pivotal role for the final DC maturation upon 
maturation induction and that the inhibition of such a pathway rather depends both on the 
check-point of the administration (CXCR4, CCR5, HLA-DR and CCR4) and/or on the 
duration of the treatment (CD40, CD80 and CD83). Our experiments cannot distinguish 
between the role played by duration and check-point of MEK inhibition by PD 98059. 
 
Interestingly, the effects of the selective MEK inhibitor U 0126 on the surface of healthy 
control-derived DCs completely mimicked those shown by the addition of the same inhibitor 
just before the loading step, with the exception of CCR4, which expression resulted 
completely inhibited. These data strongly suggest that this MEK inhibitor action, too rather 
depends on the check-point of the administration than on the duration of the treatment. In the 
case of its effects upon CCR4, it seems that a prolonged exposure reverses the effects driven 
by a short, timely inhibitor addition. The addition of the selective MEK inhibitor PD 98059 
just before maturing to patient-derived DCs mimicked the effects shown by the addition of the 
same inhibitor from the loading step. Therefore the data suggest that, at least in in vitro 
culture, MEK plays a pivotal role for the final DC maturation upon maturation induction and 
that the inhibition of such a pathway rather depends on the check-point of the administration 
than on the duration of the treatment. 
 
Interestingly, the use of the two different MEK inhibitors showed that the response of the DCs 
to such a treatment is mostly check-point exposure dependent and that the cancer 
establishment plays a pivotal role on the cell response pattern. 
 
JNK-inhibition just maturing the cells completely mimicked the effects shown upon addition 
of the same inhibitor from the very start of cell culture or just before the loading step, 
suggesting that the effects of this inhibition upon DC maturation does depend more on the 
check-point of administration rather than on its duration. Since no significant differences were 
detectable between healthy donor- and patient-derived DCs, it seems that the cancer 
establishment does not affect in a relevant way this pathway. 
 
Interestingly p38-inhibition of healthy-control derived DCs from the maturing step showed 
weaker effects in comparison to those shown upon exposure from the start and from the 
loading step regarding the impairment of CD80, CCR5 and HLA-DR; whereas the effects 
were similar concerning CD40, CXCR4 and CCR4 expression. These data suggest a different 
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pathway of action of such an inhibitor upon different maturation markers. Indeed, the 
expression of CD80, CCR5 and HLA-DR seems to require the p38-pathway from the loading 
step on and/or that p38 inhibition must be prolonged in order to increase its effects. On the 
other hand, the expression of CD40, CXCR4 and CCR4 seems to become p38-dependent 
upon maturation. 
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Fig. 14: Phenotype of mature cells inhibited from the maturation step 
 (two different humans: control 1 and patient A) 
 
3 ELISA (IL-10 and IL-12 secretion) 
Since our preliminary experiments about the effects of MAPK upon the morphology and the 
phenotype of DCs during their maturation showed that indeed, MEK, JNK and p38 play a 
pivotal role, we further investigated whether such effects mirrored the role of these kinases on 
DC functionality. 
IL-10 expression correlates with the induction of a tolerogenic environment, which strongly 
impairs the maturation of human DCs. Such IL is normally expressed at very low levels by in 
vitro cultured iDCs. On the contrary, IL-12 is highly secreted by mDCs according to their 
maturation stage and it increases the CTL response. 
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3.1 Addition of selective MAPK inhibitors from the start 
3.1.1 iDCs 
As expected, untreated iDCs derived either from healthy controls or cancer patients showed a 
very slight, if any, secretion of IL-10 or IL-12. The lack of IL-10 expression even at the 
immature stage is characteristic of excellent conditions of in vitro cultures of human DC, 
which support the following maturation step by minimizing eventual tolerogenic stimuli. On 
the other side, the lack of IL-12 secretion is typical of iDCs. 
 
Interestingly, treatment of iDCs with MEK inhibitor PD 98059 led to an IL-10 secretion in 
two healthy controls, but remained negative in the other healthy individual and in the patients. 
These results may indicate that the effects of such inhibitor are either/both dependent on the 
source (healthy controls vs cancer patients) or/and on the individual characteristics. Further 
experiments in this direction are required to solve this question. In any case, such inhibitor 
apparently may disturb the MEK-pathway in a way, which correlates with increased 
production of IL-10. As expected, no IL-12 secretion could be detected, either in the healthy 
controls or in the patients derived iDCs, reflecting their immature state. 
 
In contrast, in the supernatants of patients and the healthy controls derived iDCs treated with 
MEK-inhibitor U 0126, neither IL-10 nor IL-12 secretion was detectable. These results, very 
similar to those obtained regarding untreated cells suggest that such MEK inhibitor is unable 
to affect the MEK-pathway at the same way PD 98059.  
 
Such results suggest repeating the experiments with different concentration of PD 98059 and 
U 0126 in order to avoid artefacts and determine the real effects of such inhibitors on iDCs. 
 
The incubation with chemical inhibitor against JNK revealed very low, if any, levels of 
secreted IL-10 or IL-12 by iDCs derived from both healthy controls and patients, suggesting 
that the JNK-pathway does not influence ILs secretion by iDCs. 
 
IL-10 secretion was increased upon addition of p38 inhibitor in two controls, but was 
completely absent in all the other samples. As for PD 98059, further experiments are required 
to determine how p38-pathway is involved in the secretion of IL-10 by immature DCs. As 
expected, no IL-12 secretion could be detected, either in the healthy controls or in the 
patients’ derived iDCs, reflecting their immature state. 
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3.1.2 mDCs 
As expected, untreated mDCs, regardless of their source, do not secrete IL-10 almost at all, 
while releasing a large amount of IL-12 in the supernatant of the cell culture. Such results 
support the fact that even cancer patients-derived DCs, cultured in vitro under the described 
conditions, become able to produce levels of IL-12 comparable to those shown by healthy 
controls-derived DCs and therefore that they can be safely used in autologous immune 
therapies. 
 
Upon exposure to PD 98059 mDCs do not express almost at all IL-10, suggesting that the 
increased levels of IL-10 production at the immature state is either a transient effect or an 
artefact. The effects of this inhibitor on the production of IL-12 were minimal. These results 
suggest that the strong effects of PD 98059 on cell morphology and cell phenotype are 
uncoupled from the IL-12 production pathway. In one sentence, this inhibitor impairs the 
phenotypical but not the functional maturation of human DCs, independently of their source. 
 
Interestingly, addition of MEK-inhibitor U 0126 led to an increased secretion of IL-10 in 
mDCs, an effect particularly evident in mDCs derived from healthy controls in comparison 
with mDCs derived from cancer patients. The effects of such an inhibitor showed as well a 
strong individual-dependent pattern, in contrast to that shown upon iDCs. Such data suggest 
that the effects of this inhibitor correlate either/both with treatment duration or/and maturation 
stage. Further experiments are required to answer to such a question. Interestingly, in contrast 
to PD 98059, U 0126 affects less the phenotype and more the functionality of mDCs, 
independently of their source. Moreover, the effects of such inhibitor are well detectable on 
both phenotype and functionality, possibly according to the fact that U 0126 is known to be a 
stronger MEK inhibitor in comparison to PD 98059. The levels of IL-12 secretion were 
comparable (or slightly decreased) to those observed in untreated cells, suggesting that the 
role of MEK may be to impair IL-10 production rather than increase the levels of IL-12. In 
any case, MEK function appears to be linked to cell differentiation.  
 
JNK inhibition mildly correlated with increased secretion of IL-10, a characteristic, which 
appears to be individual-specific and independent from the DCs source, and with a strongly 
decreased production of IL-12, source- and individual-independent. Such pattern of effects 
correlates well with the results about cell morphology and phenotype observed upon JNK 
inhibition. Indeed, inhibition of JNK maintains an immature phenotype, which correlates with 
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the establishment of an impaired functionality of the mDCs. Curiously, if MEK inhibitions 
appear to increase the levels of IL-12, JNK inhibition correlates with decreased IL-12 
secretion, suggesting that possible MEK impairs IL-10 production while JNK increases IL-12 
secretion upon DCs maturation. 
 
Treatment with p38-inhibitor correlated with mild to strong induced IL-10 secretion, which 
appears to be individual- but not source-dependent. As in the case of JNK inhibitor treatment, 
the addition of p38 inhibitor strongly impaired IL-12 secretion, suggesting that p38 is required 
for both phenotypical and functional maturation of human DCs. In comparison to JNK, p38 
inhibition appears to be stronger in the effects and very similar if not identical in the pattern, 
according to the data reported in literature. 
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Fig. 15: IL-10 and IL-12 secretion of dendritic cells inhibited from the start of the culture  
 (three patients and three controls) 
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3.2 Addition of selective MAPK inhibitors from the loading step 
In order to determine: 
– whether the effects shown upon selective inhibition of different MAPKs were due to 
the prolonged exposure to such substances or whether their effects upon the DC 
maturation depend as well or principally on the time point at which they are added; 
– whether the addition of the inhibitors affects at the same time phenotype and cell 
functionality synergistically, 
we tested the effects of selective inhibition of MEK, JNK and p38, upon addition of the 
respective inhibitor just before performing the loading step. 
As expected, untreated mDCs derived from both healthy controls and patients did not secrete 
IL-10 while producing high amounts of IL-12, which levels of expression varied from 
individual to individual and which appear to be higher in patients’- rather than in healthy 
controls-derived mDCs.  
 
Regarding IL-10 and IL-12 secretion, exposure to PD 98059 from the loading step completely 
mimicked the effects observed upon long-lasting incubation mDCs, confirming that the strong 
effects of PD 98059 on cell morphology and cell phenotype are uncoupled from the IL-12 
production pathway. The secretion pattern of IL-12 showed a very individual specific 
phenotype. 
 
As observed upon prolonged exposure, addition of MEK-inhibitor U 0126 led to an increased 
secretion of IL-10 in mDCs, an effect particularly evident in mDCs derived from healthy 
controls in comparison with mDCs derived from cancer patients. IL-10 secretion levels appear 
again to be individual-specific. Again, the effects of such inhibitor are well detectable on 
both, phenotype and functionality, in comparison to PD 98059. The levels of IL-12 secretion 
were again comparable (or slightly decreased) to those observed in untreated cells, strongly 
pointing out that the role of MEK may be to impair IL-10 production rather than increase the 
levels of IL-12. In any case, MEK function was confirmed to be linked to cell differentiation.  
 
JNK inhibition correlated with increased secretion of IL-10, which differently from what 
observed upon prolonged exposure to this inhibitor, appears to be less individual-specific and 
more depending on the donor group. As already observed upon prolonged incubation, the 
levels of IL-12 were strongly down-regulated, again with a pattern, which is less individual-
specific and more depending on the donor group. Such results suggest that the effects of JNK 
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on DC maturation may be differently modulated according to the cell stage. Anyhow, 
inhibition of JNK maintains an immature phenotype, which correlates with the establishment 
of an impaired functionality of the mDCs, confirming the role of JNK in cell differentiation. 
 
Treatment with p38-inhibitor correlated with mild to strong induced IL-10 secretion, which 
appears to be individual- and source-dependent. As in the case of JNK inhibitor treatment, the 
addition of p38 inhibitor strongly impaired IL-12 secretion, suggesting that p38 is required for 
both phenotypical and functional maturation of human DCs, and appeared to be somehow 
differently modulated according to the administration way. As already observed upon 
prolonged exposure, in comparison to JNK, p38 inhibition appears to be stronger in the 
effects and very similar if not identical in the pattern, according to the data reported in 
literature. 
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Fig. 16: IL-10 and IL-12 secretion of dendritic cells inhibited from the loading with Survivin mRNA  
 (three patients and three controls) 
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3.3 Addition of selective MAPK inhibitors from the maturation step 
IL-10 and IL-12 secretion levels were finally analysed upon addition of selective MAPK 
inhibitors from the maturation step, in order to get more insights about the effects of the 
analysed MAPK pathway during the different stage of DCs maturation.  
 
As expected, untreated mDCs derived from both healthy controls and patients almost did not 
secrete IL-10 while producing high amounts of IL-12, which levels of expression varied from 
individual to individual.  
 
Regarding IL-10 and IL-12 secretion, exposure to PD 98059 from the maturing step 
completely mimicked the effects observed upon long-lasting incubation or addition from 
loading step, confirming that the strong effects of PD 98059 on cell morphology and cell 
phenotype are uncoupled from the IL-12 production pathway. The secretion pattern of IL-12 
showed again a very individual specific phenotype. 
 
As observed upon prolonged exposure or addition at the loading step, addition of MEK-
inhibitor U 0126 led to an increased secretion of IL-10 in mDCs, but differently from the 
previous experiments, such effects were individual- but not source-specific. The effects of 
such inhibitor were well detectable on both phenotype and functionality, in comparison to 
PD 98059. The levels of IL-12 secretion were almost always comparable to those observed in 
untreated cells, but showed again an individual- but not source-specificity. These results 
suggest that addition of U 0126 just before inducing maturation may modulate in a quite 
different way human DCs, suggesting that MEK-pathway is particularly crucial for such stage 
of DC maturation. 
 
JNK inhibition before maturation strongly increased the effects on IL-10 and IL-12 
expression, observed upon incubation from the loading point, suggesting that the JNK-
pathway is strongly linked to ILs secretion by mature, probably by affecting the ratio between 
IL-12 and IL-10. The real mechanism below such effects requires further investigations.  
 
Treatment with p38-inhibitor correlated with strongly induced IL-10 secretion, which appears 
to be both individual- and source-dependent, although such effect was particular evident in 
the patients-derived DCs. As in the case of JNK inhibitor treatment, the addition of p38 
inhibitor strongly impaired IL-12 secretion, suggesting that p38 is required for both 
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phenotypical and functional maturation of human DCs. Indeed, the results that the synergy 
between p38, JNK and MEK are required to induce the secretion of IL-12 and IL-10 at 
appropriate levels, probably through both, positive and negative feed-back loops.  
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Fig. 17: IL-10 and IL-12 secretion of dendritic cells inhibited from the maturation step  
 (three patients and three controls) 
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4 Proliferation assay (mixed lymphocyte reaction) 
Since we showed that human DCs maturation, studied according to morphology, phenotype 
and ILs production, was strongly affected by chemical inhibition of MAPK, JNK and p38, we 
further investigate whether such effects correlated with impaired capability to stimulate 
lymphocyte proliferation, a hallmark of mature and fully active DCs, measured by means of a 
mixed lymphocyte reaction (MLR). The proliferation rate is normalized to the proliferative 
potential of immature cells, which is set to the value of 1. The proliferation rate of the 
lymphocytes induced by mature DCs is given as relative proliferation rate compared to that 
shown by the immature cells. 
4.1 Addition of selective MAPK inhibitors from the start 
As expected, non-inhibited mDCs derived from healthy controls as well as from patients 
stimulated the proliferation of lymphocytes at a very high rate, which was similar in mDCs of 
both sources. This characteristic to induce proliferation of T-cells, which is in agreement with 
the literature, showed again the quality of the culture conditions, which leads to fully mature 
and functional mDCs. 
 
Prolonged exposure to the MEK-inhibitor PD 98059 caused a strong inhibition of the 
proliferative capability of DCs, independently of their source and very slightly individual-
specific. Interestingly such inhibition caused as well morphology and phenotypical changes 
according to the impairment of DC maturation, while it did not really affect either the levels 
of secretion of IL-12 and IL-10 or their ratio. These data suggest that the induction of 
lymphocyte proliferation may be only partially dependent on IL-12 secretion, while being 
more dependent on the morphology and the phenotype of the cells. This finding would be in 
accordance with Redy et al., who showed the importance of DCs phenotype for the stochastic 
encounters with the lymphocytes, in order to stimulate the proliferation of the latter. In this 
case, IL-12 levels will activate the lymphocyte only once they are become in touch with the 
DCs, through the dendrits. 
 
Both addition of MEK U 0126 and p38 inhibitors completely impaired the lymphocyte 
proliferation induced by DCs, while JNK inhibition had just slightly weaker effects.  
Whether such results depend on the morpho-phenotypical effects of these inhibitors or on 
their effects on the secretion of IL-12 and IL-10 or on a synergy of these two effects, it 
remains to be investigated. 
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Fig. 18: relative proliferation rate of lymphocytes induced by dendritic cells inhibited from the start of the  
 culture (three patients and three controls) 
 
4.2 Addition of selective MAPK inhibitors from the loading step 
The addition of MEK inhibitors PD 98059 and U 0126, as well as of JNK and p38 selective 
inhibitors from the loading step instead of inhibition from the very beginning of the culture, 
completely mimicked the effects observed in the latter case, suggesting that the modulation in 
cell phenotype and in the pattern of IL-10 and IL-12 production, shown in the previous 
experiments according to the inhibitor administration window, do not affect the induction of 
lymphocyte proliferation, which in turn appears to be strongly dependent on the morphology, 
in comparison to the response to IL-12 secretion. 
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Fig. 19: relative proliferation rate of lymphocytes induced by dendritic cells inhibited from the loading  
 with Survivin mRNA (three patients and three controls) 
 
4.3 Addition of selective MAPK inhibitors from the maturation step 
The addition of MEK inhibitors PD 98059 and U 0126, as well as of JNK and p38 selective 
inhibitors from the maturing step instead of the inhibition from the very beginning of the 
culture or from the loading step, completely mimicked the effects observed in the latter cases, 
pointing out that the induction of lymphocyte proliferation by human DCs is strongly 
dependent on the morphology, in comparison to the response to IL-12 secretion, which 
appears however to be able to induce a weaker and possibly independent lymphocyte 
proliferation. 
Further experiments about the exact mechanism below the release of IL-12 and IL-10 as well 
as their function upon DC-lymphocytes encounter are needed. 
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Fig. 20:  relative proliferation rate of lymphocytes induced by dendritic cells inhibited from the  
 maturation step (three patients and three controls) 
 
5 Phagocytosis assay (FITC-Dextran-uptake) 
In order to be able to induce proliferation of lymphocytes, DCs need to phagocyte exogenous 
antigens. Therefore, such characteristic is a typical feature of iDCs, while once they have been 
loaded with an antigen, mDCs lose the capability to endocyte further. Since we observed that 
the inhibition of each MAPK pathway strongly impaired human DCs in vitro maturation, we 
investigated whether such morphological, phenotypical and functional characteristic 
correlated with increased amount of activities, typical for iDCs. The phagocytosis property of 
DCs is determined through the rate of FITC-dextran uptake, which is given in percentage of 
cells, which take up the labelled dextran. In order to determine the effects of maturation on 
the phagocytotic capability, the cells were induced by addition of CCL19, the ligand of 
CCR7, a surface marker expressed exclusively by mDCs. 
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5.1 Addition of selective MAPK inhibitors from the start 
5.1.1 iDCs 
As expected, untreated iDCs, independently of their source, showed the highest phagocytosis 
capability, unable to respond to CCL19 induction. This was independent as well of the 
addition of any MAPK inhibitors, suggesting that these pathways are not crucial for 
phagocytosis, at least when the DCs are immature.  
 
5.1.2 mDCs 
As expected, upon maturation, DCs lost completely or almost completely their spontaneous 
and CCL19-induced phagocytosis capabilities, independently of their source.  
 
In contrast, inhibition of MEK-pathway with PD 98059 correlated with a very slight decrease 
of the phagoytosis capabilities, a feature, which showed both, individual and to some extend 
source specific characteristics, above all regarding CCL19-induction effects. They appear 
indeed to be stronger in healthy controls’ than in patients’ derived DCs.  
 
Inhibition of the MEK-pathway, using inhibitor U 0126, showed effects similar to those 
observed for PD 98059 regarding the pattern and the levels of phagocytosis capability. In this 
case the effects of CCL19 induction are less significant. 
 
Both JNK and p38 inhibition caused the same effects obtained upon addition of both MEK 
inhibitors, but less strong in the levels. The major difference is that upon inhibition of JNK 
and p38-pathways, CCL19 induction is particularly effective to induce phagocytosis, 
especially in the patients’ derived DCs, while being more individual-specific and less 
significant in healthy controls’ derived DCs. 
 
These results suggest that all the analysed pathways have paramount effects on DC 
maturation, but they reach their goal through different ways. Indeed, while JNK and p38 
inhibition seems to be more dependent on CCL19 induction, showing a linkage to the 
expression of specific surface markers, MEK inhibition appears to be less dependent on the 
phenotype, at least for what concerns the phagocytosis properties. It can as well be that the 
morphology of the cells plays a major role regarding this feature. Further experiments in this 
direction are needed to clarify this point. 
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Fig. 21: phagocytosis potential of dendritic cells inhibited from the start of the culture 
 (three patients and three controls) 
 
5.2 Addition of selective MAPK inhibitors from the loading step 
As expected, upon maturation, DCs lost completely or almost completely their spontaneous 
and CCL19-induced phagocytosis capabilities, independently of their source. 
 
Both PD 98059 and U 0126 driven inhibition of MEK correlated with increased levels of 
phagocytosis, comparable with those observed in the previous set of experiments. Such 
effects as well as those related to CCL19 exposure appeared extremely individual rather than 
source specific. 
 
JNK inhibition increased the basal levels of phagocytosis in comparison with those shown by 
untreated cells and a strong positive induction upon exposure to CCL19 in patients’ derived 
DCs and an individual-depending pattern in healthy controls derived DCs.  
 
The effects observed upon JNK inhibition were strengthened upon inhibition with p38. 
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Inhibition from the loading with Survivin mRNA 
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Fig. 22: phagocytosis potential of dendritic cells inhibited from the loading with Survivin mRNA 
 (three patients and three controls) 
 
5.3 Addition of selective MAPK inhibitors from the maturation step 
As expected, upon maturation, DCs lost completely or almost completely their spontaneous 
and CCL19-induced phagocytosis capabilities, independent of their source.  
 
In contrast, inhibition of MEK-pathway with PD 98059 correlated with a more pronounced 
decrease of the phagoytosis capabilities, in comparison to the observations made for cultures 
added up with this inhibitor from the start. The effects of CCL19 were very individual-
specific, more than source dependent.  
 
Inhibition of the MEK-pathway, using inhibitor U 0126, showed effects similar to those 
observed for PD 98059 regarding the pattern and the levels of phagocytosis capability. In this 
case the effects of CCL19 induction were particular significant in inducing phagocytosis, in 
contrast with what was observed upon prolong incubation with such an inhibitor. 
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These results showed that MEK inhibition efficacy depends on longer incubation and/or on 
addition of the inhibitor at the immature stage. Further experiments are required to monitor 
such effects. 
JNK inhibition increased the basal levels of phagocytosis in comparison with those shown by 
untreated cells and a strong positive induction upon exposure to CCL19 especially in patients’ 
derived DCs and a more individual-depending pattern in healthy controls’ derived DCs. 
 
The effects observed upon JNK inhibition were strengthened upon inhibition with p38. 
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Fig. 23: phagocytosis potential of dendritic cells inhibited from the maturation step 
 (three patients and three controls) 
 
6 Migration Assay (Transwell assay) 
Finally, we investigated the effects of MAPKs on the migratory potentialities, which as well 
as the phagocytosis are hallmark of immature DCs. 
The migration assay is carried out as a transwell assay. The results are given in percentage of 
migrated cells (spontaneous or induced) relative to the total cell number.  
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6.1 Addition of selective MAPK inhibitors from the start 
6.1.1 iDCs 
As expected, immature DCs are particular active in migration, do not respond to CCL19 
exposure due to the absence of the respective receptor, CCR7 and as shown in the previous 
experiments as well, they almost do not respond to any MAPK inhibition. 
 
6.1.2 mDCs 
In contrast to iDCs, mDCs almost completely lost their migratory potentialities and almost did 
not respond to CCL19 exposure. 
 
Upon inhibitor PD 98059 or with U 0126, the mDCs showed increased migration and a 
significant positive induction of this parameter upon incubation with CCL19. 
 
The same effects observed upon MEK inhibition were as well observed upon inhibition of 
JNK and mostly upon p38-inhibition, supporting the theory that the three MAPKs work in a 
positive feedback loop. Both JNK and p38 inhibition showed a striking CCL19-dependent 
increased migration.  
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Fig. 24: migration of dendritic cells inhibited from the start of the culture 
 (three patients and three controls) 
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6.2 Addition of selective MAPK inhibitors from the loading step 
The same results observed during prolonged incubation with MAPK inhibitors were found if 
the respective inhibitors were added just before the loading step. In this case, however, MEK 
inhibition showed a more individual-like CCL19 specificity, while JNK and p38 inhibition 
caused increased migration upon CCL19 addition. 
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Fig. 25: migration of dendritic cells inhibited from the loading with Survivin mRNA 
 (three patients and three controls) 
 
6.3 Addition of selective MAPK inhibitors from the maturation step 
The same results observed upon addition before the loading step with MAPK inhibitors were 
observed if the respective inhibitors were added just before maturation. In this case, the 
effects of CCL19 were less striking and more individual-specific.  
These results showed that according to the different exposure time, MAPKs inhibition may 
show a different pattern of effects, suggesting that the three kinases may modulate DCs 
migration according to various mechanisms, which details remain presently unknown. 
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Inhibition from the maturation step 
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Fig. 26: migration of dendritic cells inhibited from the maturation step 
 (three patients and three controls) 
 
7 Viability assay 
In order to finally investigate the role of the three MAPKs during DC maturation, we 
investigated as well their effects on cell viability, through a viability assay based on Annexin-
V-FITC detection. The viability of mDCs was decreased to a rate of about one quarter of the 
total cell number independent of their source. Cells were cultured in presence of the relative 
inhibitors from the start of the culture. 
 
Normal cell viability of untreated cells was around 75%. This rate was strongly decreased 
upon addition of specific inhibitors of the MAPKs. MEK inhibition through PD 98059 or 
U 0126 caused a reduction of cell viability of around 15-23%, with effects, which appear to 
have an individual-dependent component. JNK and p38 inhibition caused as well an 
impairment of cell viability of around 20 to 25%, respectively.  
 
These results seem to indicate that the three analysed MAPK pathways are required for a 
normal cell viability of human DCs. However, due to the potential toxicity of such inhibitors, 
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further experiments regarding titration of the used inhibitors are needed to determine the real 
worth of this test. 
 
 A B C D E 1 2 3 4 5 6 
Control 73,20 80,30 71,20 74,80 76,10 72,60 78,40 70,90 81,20 80,40 78,60 
PD 53,70 55,90 56,30 50,80 51,20 50,70 61,20 65,40 54,30 69,80 59,10 
U 48,30 58,90 55,90 50,80 53,90 60,80 67,40 66,20 70,20 59,80 50,80 
JNK 59,30 65,50 48,70 45,80 50,70 55,40 52,10 50,80 45,60 44,90 50,80 
p38 41,90 43,90 38,70 43,20 45,20 50,90 50,80 55,40 56,30 50,90 60,80 
Table 10: Percentage of viable cells (five patients and six controls) 
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Fig. 27: Viability assay from mature dendritic cells without or with inhibition from the start of the culture 
 (five patients and six controls) 
 
8 Western Blot 
Due to the fact that an indirect analysis of the MAPKs pathways through cell morphology, 
phenotype and different functionalities showed that MEK, JNK and p38 play a crucial role for 
the final maturation of human DCs and that they may be dependent to different extends on 
individual characteristics as well as from their source, i.e. healthy people or cancer patients, 
we investigated the expression of such kinases in untreated as well as inhibited cell cultures of 
human DCs by WB analysis. The cytoplasmatic fractions of the protein lysates are obtained 
by Frackelton lysis from mDCs derived from patient A, suffering from colon cancer. These 
cells are incubated without or with inhibitors from the start of the culture. 
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8.1 MEK, C-Raf and B-Raf 
MEK 
The antibody against phospho-MEK 1/2 selectively detects phosphorylated Serine 217 and 
Serine 221. The size of this phosphorylated MEK 1/2 is identical to the unphosphorylated 
form, which is 45kDa. MEK 1/2 antibody recognizes endogenous levels of total MEK 1/2 
protein with a size of 45kDa. 
 
 
 
 
 C PD U JNK p38 
Fig. 28: Western blot analysis of pMEK vs MEK and actin 
 
As expected, MEK expression did not change upon MAPK selective inhibition. On the 
contrary, the active forms of MEK 1/2 were strongly expressed by control cells, whereas they 
were strongly impaired upon inhibition with PD 98059 and absent upon inhibition with 
U 0126, according to the well known findings that the latter one is a stronger inhibitor of the 
MEK-pathway. Interestingly, also JNK and p38 inhibition caused the inhibition of MEK 
phosphorylation. Although the precise mechanism remains unknown, this fact further 
suggests the strong linkage among the three MAPKs in human DCs. 
 
C-Raf 
The C-Raf antibody is prepared from a human C-Raf immunogen of 216 amino acids length. 
This antibody detects the C-Raf protein, which has a size of 74kDa. Since C-Raf is strongly 
linked to the MEK-pathway, we investigated as well the effects of selective MAPK inhibition 
on the levels of such protein. 
 
 
 
 C PD U JNK p38 
Fig. 29: Western blot analysis of C-Raf and actin 
 
Differently from what expected, C-Raf was mildly expressed in untreated cells and in cells 
treated with PD 98059, while showing an increased expression upon inhibition with U 0126 
pMEK 
C-Raf 
MEK 
Actin 
Actin 
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or JNK/p38 inhibition. The real significance of such result is unknown and requires more 
experiments to be either proven or rejected.  
 
B-Raf 
Due to the inconclusive results about C-Raf and in order to get further insights about the role 
of MEK in DC maturation, we investigated the expression of B-Raf upon MAPK inhibition 
with selective chemicals. B-Raf antibody (C-19) is raised against a peptide, which is mapped 
at the C-terminus of Raf-B of human origin on chromosome 7q34. It has molecular weights of 
95kDa and 62kDa. 
 
In our case, untreated DCs showed an exclusive presence of the 62 kDa form. Cells treated 
with PD 98059 showed a strong predominance of the 95 kDa form and a very slight presence 
of the 62 kDa. Cells treated with U 0126 showed levels of expression of both the 95 kDa and 
the 62 kDa form, comparable to those observed in untreated cells. JNK inhibition decreased 
the expression of the 62 kDa isoform and there was no expression of the 95 kDa. Inhibition of 
p38 did not affect the expression of the 95 kDa isoform and caused a minimal decrease of the 
expression of the 62 kDa isoform. 
 
 
 
 C PD U JNK p38 
Fig. 30: Western blot analysis of Raf-B and actin 
 
MEK inhibition with U 0126 showed bands of balanced intensity at 62kDa as well as 95kDa. 
The JNK-inhibitor led to a decreased 62kDa band compared to the control and no B-Raf 
protein of 95kDa size could be detected. Cells grown with p38-inhibitor showed a band at 
62kDa, which is almost equal to the control and a more intense 95kDa protein signal. 
These results require further experiments in order to prove their reliability, but they seem to 
indicate that B-Raf expression may be modulated by all of the three analysed MAPK in 
different ways, which meaning is presently unknown. 
62kDa
95kDa
Actin
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8.2 JNK 
JNK 2/3 
To detect the levels of active JNK, the phosphorylated JNK is measured by means of an 
antibody recognizing phosphorylation of Threonin 183 and Tyrosin 185. 
 
SAPK or JNK antibody detects endogenous levels of total SAPK/JNK protein. The 
immunogen is a JNK2-GST-Fusion protein. The antibody recognizes the 46kDa protein JNK1 
as well as JNK2/3 which has a size of 54kDa. 
 
 
 
 
 C PD U JNK p38 
Fig. 31: Western blot analysis of pJNK vs JNK and Actin 
 
Untreated cells showed the expression of pJNK as well as cells treated with PD 98059. On the 
contrary, cells treated with U 0126, JNK and p38 inhibitor showed a strongly diminished 
expression of the phosphorylated form of JNK. These results showed again that in human 
DCs all the three MAPK pathways are required for the maturation, that they work in the same 
direction, i.e. final cell maturation, and that they are probably linked by positive feedback 
loops.  
8.3 p38 
p38 antibody recogizes the C-terminus of human p38 protein. 
The active form of p38 carries a phosphorylated Tyrosin at the position 182 in the p38 amino 
acid sequence. 
 
 
 
 
 C PD U JNK p38 
Fig. 32: Western blot analysis of p-p38 vs p38 and Actin 
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Untreated cells showed an expression of p38 as well as cells treated with PD 98059, although 
at very decreased levels. On the contrary, cells treated with U 0126, JNK and p38 inhibitor 
showed almost no expression of the phosphorylated form of p38. Shortly, the expression 
pattern of p-p38 mimicked that of pJNK, but to increased levels. These results showed again 
that in human DCs all the three MAPK pathways are required for the maturation, that they 
work in the same direction, i.e. final cell maturation, and that they are linked probably by 
positive feedback loops, which seem to affect mostly p38 phosphorylation, pointing out a 
possible more critical role for this MAPK in comparison with the other two. 
 
Discussion 
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Discussion 
The aim of this thesis has been the investigation of the role of three MAPKs pathways, i.e. 
ERK, JNK and p38 during the in vitro maturation of monocyte-derived DCs, derived from 
healthy controls’ versus cancer patients’, in order to determine their function according to the 
different stages of DC maturation and according to the health state of the single individual. 
 
Our results showed that all three pathways are of paramount importance for the right 
maturation course. Indeed, once inhibited, each of them caused a striking impairment of DC 
maturation regarding both phenotype and functionality. Completely unexpected was the 
finding that inhibition of MEK by both, PD 98059 or U 0126, caused always a strong 
impairment of DC maturation, according to the results of analyses of cell morphology, surface 
markers and functionality. On the other side, as expected, the inhibition of either JNK or p38 
led to the same effect. 
 
It appears that the three analysed kinases, during MoDCs differentiation, work together and 
interact through positive feedback loops. Anyhow, further experiments in this direction are 
required to shed new light about these pathways in the human DC differentiation. We did not 
observe striking differences between the effects of the three MAPKs inhibition according to 
their source (healthy controls or cancer patients). These results are in agreement with the fact 
that DCs derived from different sources were always in vitro cultured under conditions, set to 
induce a normal DC maturation from cancer patients´ derived monocytes. Therefore, to 
determine the real influence of cancer on MAPKs activities, other cell culture conditions may 
be eventually tested. 
 
On the other side, the effects of MAPKs inhibitions showed a clear individual-specific pattern 
in most cases. However, since the number of samples used for the analyses did not reach a 
statistical significance and patients with different types of cancer were investigated, the real 
significance of this parameter must be further ascertained. 
 
In any case, inhibition of all three MAPK caused a complete inhibition of the morphological 
maturation of human DCs. Indeed, the cells fully lose the capability to develop dendrites and 
become adherent, while keeping the round shape and the non-adherent characteristic, typical 
for immature DCs. These observations were confirmed by the phenotypical analysis of cell 
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surface parameters. Again, the selective inhibition of any MAPKs correlated with a strongly 
decreased amount of mature markers on DCs membrane. These results about the phenotype 
were mirrored by those obtained about cell functionality. Indeed, if on one hand, DCs 
selectively treated with MAPK inhibitors showed a severe impairment in IL-12 secretion and 
in the induction of allogenic T-cell proliferation, two typical hallmark of DC maturation, on 
the other hand, they showed increased levels of migration and phagocytosis as well as higher 
IL-10 production, features, which correlate with the establishment of an immature state.  
 
Cell viability was mildly affected by any selective MAPK inhibition. These data may suggest 
that in this particular case, the three analysed pathway play minor role in cell viability, but 
further experiments must confirm or refute this finding. 
 
This work aimed to analyse as well the role of the three MAPKs according to different 
maturation stages, therefore the inhibitor were added at the start, before performing the 
loading step and just before inducing maturation. The effects of selective inhibition on iDCs 
was negligible, suggesting that the three pathways are mostly crucial during loading and upon 
maturation induction, possibly driving or at least modulating the response to such stimuli. 
 
Interestingly, the effect of PD 98059 or U 0126 reached different intensity according to each 
parameter analysed. Indeed, if PD 98059 addition mostly affected the expression of mature 
surface markers on DC membrane, U 0126 mostly stimulated IL-10 production and inhibited 
the induction of allogenic T-cells proliferation. These data suggest that distinct ERK-linked 
pathways are differently involved in DC maturation. Again, further experiments are required 
to explore this possibility. 
 
On the other side, both JNK and p38 appeared to be mostly involved in the stimulation of DC 
maturation from the phenotypical and functional prospective. In any case, p38 seems to 
induce stronger effects in comparison to JNK inhibition. 
 
One interesting finding regards the levels of IL-10 and IL-12 secretion upon selective 
inhibition of the MAPKs. Indeed, it seems that MEK inhibition induced IL-10 production 
while JNK or p38 inhibition impaired IL-12 secretion. These data suggest a possible positive 
feedback loop supporting physiological DC maturation: while ERK pathway activation 
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impairs IL-10 production, the contemporaneous activation of JNK and p38 pathway induces 
the secretion of IL-12, which in turn stimulates DCs activity upon CTL response.  
 
A further striking finding is that upon PD 98059 addition, although it was observed only a 
partial inhibition of IL-12 secretion in absence of IL-10 production, we could show a very 
strong effect on the impairment of the induction of an allogenic stimulus. These data suggest 
that the induction of lymphocyte proliferation may be only partially dependent on IL-12 
secretion, while being more dependent on the morphology and the phenotype of the cells. 
This finding would be in accordance with Redy et al., who showed the importance of DCs 
phenotype for the stochastic encounters with the lymphocytes, in order to stimulate the 
proliferation of the latter ones. In this case, IL-12 levels will activate the lymphocytes only 
once they come in touch with the DCs, through the dendrits. 
 
In conclusion, this work showed that ERK, JNK and p38 pathways play a paramount role in 
phenotypical and functional maturation of human DCs. The details of the mechanisms 
underlying the establishment of the mature state are presently unknown and further 
investigations are required in this direction. However, we could show preliminary results, 
suggesting new interesting trails which may lead to a better knowledge of a type of immune 
system cells, known to be particularly effective against cancer, if correctly activated against 
specific tumour antigens. 
 
References 
 
 - 68 - 
References 
                                                 
1 Bevan M.J.: Helping the CD8(+) T-cell response. Nat. Rev. Immunol 4: 595-602 
 
2 Dudziak D. et al: Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111; 
2007 
 
3 Soares H. et al: A subset of dendritic cells induces CD4+ T-cells to produce IFN-γ by an IL-12-independent 
but CD70-dependent mechanism in vivo. J. Exp. Med. 204: 1095-1106; 2007 
 
4 Bennet L. et al: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. 
 
5 Randolph G.J., Sanches-Schmitz G., Angeli V.: Factors and signals that govern the migration of dendritic 
cells via lymphatics: recent advances. Springer Semin. Immunopathol. 26: 273-287; 2005 
 
6 Cyster J.G.: Chemokines and the homing of dendritic cells to the T-cell areas of lymphoid organs. J. Exp. 
Med. 189: 447-450; 1999 
 
7 Itano A.A., Jenkins M.K.: Antigen presentation to naive CD4 T-cells in the lymph node. Nature Immunol 4: 
733-739; 2003 
 
8 Dubois B., Massacrier C., Vanbervliet B., Fayette J., Briere F., Banchereau J. et al.: Critical role of IL-12 in 
dendritic cell-induced differentiation of naive B lymphocytes. J. Immunol. 161: 2223-2231; 1998 
 
9 Hilkens C.M., Kalinski P., de Boer M., Kapsenberg M.L.: Human dendritic cells require exogenous 
interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. 
Blood 90: 1920-1926; 1997 
 
10 Jonuleit H., Schmitt E., Schuler G., Knop J., Enk A.H.: Induction of interleukin 10-producing, 
nonproliferating CD4+ T-cells with regulatory properties by repetitive stimulation with allogeneic immature 
human dendritic cells. J. Exp. Med. 192: 1213-1222; 2000 
 
11 Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S.: Escape of human solid tumors from T-cell 
recognition: molecular mechanisms and functional significance. Adv. Immunol 74: 181-273; 2000 
 
12 Whiteside T.L.: Immune cells in the tumor microenvironment: Mechanisms responsible for functional and 
signaling defects. Adv. Exp. Med. Biol. 451: 167-171; 1998 
 
13 Romani N., Reider D., Heuer M., Ebner S., Kampgen E., Eibl B., Niederwieser D., Schuler G.: Generation of 
mature dendritic cells from human blood. An imporved method with spezial regard to clinical applicability. J. 
Immunol. Methods 196: 137-151; 1996 
 
14 Steinbrink K., Wolfl M., Jonuleit H., Knop J., Enk A.H.: Induction of tolerance by IL-10-treated dendritic 
cells. J. Immunol. 159: 4772-2780 
 
15 Sallusto F., Lanzacecchia A.: Efficient presentation of soluble antigen by cultured human dendritic cells is 
maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by 
tumor necrosis factor α. J. Exp. Med. 179: 1109-1118; 1994 
 
16 Zhou L.J., Tedder T.F.: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic 
cells. Proc. Natl. Acad. Sci. 93: 2588-2592; 1996 
 
17 Dieckmann D., Schultz E.S., Ring B., Chames P., Held G., Hoogenboom H.R. et al: Optimizing the 
exogenous antigen loading of monocyte-derived dendritic cells. Int. Immunol 17: 621-635; 2005 
 
18 Karp C.L., Wysocka M., Ma X., Marovich M., Factor R.E., Nutman T. et al: Potent suppression of IL-12 
production from monocytes and dendritic cells during endotoxin tolerance. Eur. J. Immunol 28: 3128-3136; 
1998 
 
References 
 
 - 69 - 
                                                                                                                                                        
19 Velders M.P., Markiewicz M.A., Eiben G.L., Kast W..M.: CD4+ T cell matters in tumor immunity. Int. Rev. 
Immunol. 22:113-140; 2003 
 
20 Bohnenkamp H.R., Coleman J., Burchell J.M., Taylor-Papadimitriou J., Noll T.: Breast carcinoma cell 
lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T-cells identified by peptide-MHC-class-I 
tetramers. Cell Immunol 231:112-125; 2004 
 
21 Van Tendeloo V.F., Snoeck H.W., Lardon F., Vanham G.L., Nijs G., Lenjou M., Hendriks L., Van 
Broeckhofen C., Moulijn A., Rodrigus I., Verdonk P., Van Bockstaele D.R., Berneman Z.N.: Nonviral 
transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into 
hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Ther. 5: 700-707; 1998 
 
22 Nair S.K., Boczkoswski D., Morse M., Cumming R.I., Lyerly H.K., Gilboa E.: Induction of primary 
carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells 
transfected with RNA. Nat. Biotechnol 16: 364-369; 1998 
 
23 Su Z., et al: Enhanced induction of telomerase-specific CD4+ T cells using dendritic cells transfected with 
RNA encoding a chimeric gene product. Cancer Res. 62: 5041-5048; 2002 
 
24 Zeis M., et al: Generation of cytotoxic responses in mice and human individuals against hematological 
malignancies using survivin-RNA-transfected dendritic cells. J. Immunol. 170: 5391-5397; 2003 
 
25 Ambrosini G., Adida C., Altieri D.C.: A novel anti-apoptosis gene, survivin, expressed in cancer and 
lymphoma. Nature Med. 3: 917-921; 1997 
 
26 Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C.: Developmentally regulated 
expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Path. 
152: 43-49; 1998 
 
27 Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C.: Control of apoptosis and 
mitotic spindle checkpoint by survivin. Nature 396: 580-584; 1998 
 
28 Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., Wen S.F., Wang L., Kirschmeier P., 
Bishop W.R., Nielsen L.L., Pickett C.B., Liu S.: Human survivin is negatively regulated by wild-type p53 
and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622; 2002 
 
29 Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., Dombret H., Reyes F., Diebold J., 
Gisselbrecht C., Salles G., Altieri D.C., Molina T.J.: Prognostic significance of survivin expression in diffuse 
large B-cell lymphomas. Blood 96: 1921-1925; 2000 
 
30 Wurl P., Kappler M., Meye A., Bartel F., Kohler T., Lautenschlager C. Bache M., Schmidt H., Taubert H.: 
Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. 
Lancet 359: 943-945; 2002 
 
31 Arrighi J.F., Rebsamen M., Rousset F., Kindler V., Hauser C.: A critical role for p38 mitogen-activated 
protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-
alpha, and contact sensitizers. J. Immunol 166: 3837-3845; 2001 
 
32 Verhasselt V. Buelens C. Willems F., De Groote D., Haeffner-Cavaillon N., Goldman M. Bacterial 
lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by 
human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J. Immunol 
158:2919-25; 1997 
 
33 Nakagawa S., Ohtani T., Mizuashi M., Molla Z. Ito Y., Tagami H., Aiba S.: p38 Mitogen-activated protein 
kinase mediates dual role of ultraviolet B radiation in induction of maturation and apoptosis of monocyte-
derived dendritic cells. J. Invest. Dermatol. 123: 361-370; 2004 
 
34 Widmann C., Gibson S., Jarpe M.B., Johnson G.L.:Mitogen-Activated Protein Kinase: Conservation of a 
three-kinase module from yeast to human. Physiological Reviews 79: 143-180; 1999 
 
References 
 
 - 70 - 
                                                                                                                                                        
35 Gartner A., Nasmyth K., Ammerer G.: Signal transduction in Saccharomyces cerevisiae requires tyrosine and 
threonine phosphorylation of FUS3 and KSS1. Genes and development 6: 1280-1292; 1992 
 
36  Fanger G.R., Lassignal-Johnson N., Johnson G.L.: MEK kinases are regulated by EGF and selectively 
interact with Rac/Cdc42. EMBO J. 16: 4961-4972; 1997 
 
37  Koide H., Satoh T., Nakafuku M., Kaziro Y.: GTP-dependent association of Raf-1 with Ha-Ras: 
identification of Raf as a target downstream of Ras in mammalian cells. Proc. Natl. Acad Sci. 90: 8683-8686; 
1993 
 
38  Marais R., Light XY., Paterson H.F., Mason C.S., Marshall C.J.: Control of the ERK MAP kinase cascade by 
Ras and Raf. Cancer Surv. 27: 101-125;1996 
 
39 Downward J.: Control of ras activation. Cancer Surv. 27: 87-100; 1996 
 
40  Marais R., Light Y., Paterson H.F. Marshall C.J.: Ras recruits Raf-1 to the plasma membrane for activation 
by tyrosine phosphorylation. EMBO J. 14: 3136-3145; 1995 
 
41  Marais R., Light Y., Paterson H.F., Mason C.S., Marshall C.J.: Differential regulation of Raf-1, A-Raf and B-
Raf by oncogenic Ras and tyrosine kinases. J. Biol. Chem. 272: 4378-4383; 1997 
 
42 Mischak H., Seitz. T., Janosch P., Eulitz M., Stehen H., Schellerer M., Philipp A., Kolch W.: Negative 
regulation of Raf-1 by phosphorylation of serine 621. Mol. Cell. Biol. 16: 5409-5418; 1996 
 
43  Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S., Stork P.J.: cAMP activates MAP kinase and Elk-1 
through a B-Raf- and Rap1-dependent pathway. Cell 89: 73-82; 1997 
 
44 Widmann C., Lassignal-Johnson N., Gardner A.M., Smith R.J., Johnson G.L.: Potentiation of apoptosis by 
low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene 15: 2439-2447; 1997 
 
45 Yang D.D, Kuan C.Y., Whitmarsh A.J., Rincon M., Zheng T.S., Davis R.J., Rakic P., Flavell R.A.: Absence 
of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389: 865-870; 
1997 
 
46 Pulverer B.J., Kyriakis J.M., Avruch J., Nikolakaki E., Woodgett J.R.: Phosphorylation of c-jun mediated by 
MAP kinases. Nature 353: 670-674; 1991 
 
47 Gupta S., Campbell D., Derijard B., Davis R.J.: Transcription factor ATF2 regulation by the JNK signal 
transduction pathway. Science 267: 389-393; 1995 
 
48 Hu M.C., Qiu W.R., Wang Y.P.: JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 15: 
2277-2287; 1997 
 
49 Heasley L.E., Han S.Y.: JNK regulation of oncogenesis. Molecules and Cells 21: 167-173; 2006 
 
50 Potapova O., Basu S., Mercola D., Holbrook NJ.: Protective role for c-Jun in the cellular response to DNA 
damage. Journal of biological chemistry 276: 28546-28553; 2001 
 
51 Hayakawa J., Mittal S., Wang Y., Korkmaz K.S., Adamson E., English C., Ohmichi M., McClelland M., 
Mercola D.: Identification of promoters bound by c-Jun/AFT2 during rapid large-scale gene activation 
following genotoxic stress. Molecular Cell 16: 521-535; 2004 
 
52 Ono K., Han J.: The p38 signal transduction pathway: activation and function. Cell Signal. 12: 1-13; 2000 
 
53 Whitmarsch A.J., Davis R.J.: Transcription factor AP-1 regulation by mitogen-activated protein kinase signal 
transduction pathways. J. Mol. Med. 74:589-607; 1996 
 
54 Jiang Y., Gram H., Zhao M.: Characterization of the structure and function of the fourth member of p38 
group mitogen-activated protein kinases, p38δ. J. Biol. Chem. 272: 30122-30128; 1997 
 
References 
 
 - 71 - 
                                                                                                                                                        
55 Kramer R.M., Roberts E.F., Um S.L.: p38 mitogen-activated protein kinase phosphorylates cytosolic 
phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation 
is not required for mobilization of arachidonic acid by cPLA2. J. Biol. Chem. 271: 27723-27729; 1996 
 
56 Zwang Y., Yarden Y.: p38 MAP kinase mediates stress-induced internalization of EGFR: implications for 
cancer chemotherapy. EMBO J. 25:4195-4206; 2006 
 
57 Farley N., Pedraza-Alva G., Serrano-Gomez D.: p38 mitogen-activated protein kinase mediates the Fas-
induced mitochondrial death pathway in CD8+ T cells. Mol. Cell. Biol. 26:2118-2129; 2006 
 
58 Zervos A.S., Faccio L., Gatto J.P., Kyriakis J.M., Brent R.: Mxi2, a mitogen-activated protein kinase that 
recognizes and phosphorylates Max protein. Proc. Natl. Acad. Sci. 92: 10531-10534; 1995 
 
59 Liu Y., Shepherd E., Nelin L.: MAPK phosphatases – regulating the immune response. Nature immunology 
reviews 7: 202-212; 2007 
 
60 Pedersen A.E., Thorn M., Gad M., Walter M.R:, Johnsen H.E., Gaarsdal E., Nikolajsen K., Buus S., Claesson 
M.H., Svane I.M.: Phenotypic and functional characterization of clinical grade dendritic cells generated from 
patients with advanced breast cancer for therapeutic vaccination. Scand. J. Immunol. 61: 147-156; 2005 
 
61 Pages G., Lenormand P., L’Allemain G., Chambard J.C., Meloche S., Pouyssegur J.: Mitogen-activated 
protein kinase p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. USA 
90: 8319-8323; 1993 
 
62 Ono K., Han J.: The p38 signal transduction pathway: activation and function. Cell Signal 12: 1-13; 2000 
 
63 Leppä S., Saffrich R., Ansorge W., Bohmann D.: Differential regulation of c-Jun by ERK and JNK during 
PC12 cell differentiation. EMBO J. 17: 4404-4413; 1998 
 
64 Babath J., Rollig C., Oelschlagel U., Zhao S., Ehninger G., Schmitz M., Bornhauser M.: Large-scale 
immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a 
phase I study. J. Hematother. Stem Cell Res 12: 515-523 
 
CURRICULUM VITAE 
 
PERSONAL HISTORY: 
Name: Marianne Raith 
Place and date of birth: Hollabrunn, 6th of April 1978 
Address: A-2023 Nappersdorf 30 
Mail: Marianne-Raith@gmx.at 
Nationality: Austria 
 
EDUCATION: 
10/2000-11/2001 
and since 03/2004: studies at the university of vienna “molecular biology” 
October 2000: Diploma „Medical Technician“ passed with distinction 
1997-2000: School for medical technicians at the General Hospital of 
Vienna 
1992-1997: Handelsakademie, Hollabrunn (commercial academy), 
passed with distinction 
1988-1992: Hauptschule Wullersdorf (secondary school) 
1984-1988: Volksschule Nappersdorf (primary school) 
 
WORKING EXPERIENCE: 
7/2000 to10/2002: Medical University Vienna, Clinical Institute of Medical 
and Chemical Laboratory Diagnostics 
 “The role of E-selectin polymorphism in the pathogenesis 
of diabetes-associated microangiopathy“ 
 Direction: Oswald Wagner, MD; Markus Exner, MD 
  
10/2002-9/2004: Medical University Vienna, Clinical Institute of Medical 
and Chemical Laboratory Diagnostics 
 “Heme oxygenase-1 and atherosclerosis” 
 Direction: Markus Exner, MD  
 
9/2004-4/2006: Medical University Vienna, Clinical Institute of Medical 
and Chemical Laboratory Diagnostics 
 “The role of Hedgehog signaling pathways in human and 
mouse” 
 Direction: Harald Esterbauer, MD, PhD 
 
5/2006-2/2007: Medical University Vienna, Clinical Institute of Medical 
and Chemical Laboratory Diagnostics and CEMM, Center 
of Molecular Medicine  
 “The role of natural antibodies in atherosclerosis” 
 Direction: Christoph Binder, MD, PhD 
 
03/2007-12/2007: Diploma thesis at CellMed Research GmbH 
 “The role of MAPK pathways in in vitro maturation of 
dendritic cells, cultured from patients’ peripheral blood-
monocytes“ 
 Direction: Wolfgang J. Schneider, PhD; Cristina Rubiolo, PhD 
